

Reference Section I
patient survival



table i.1 · 492
incident patient counts: esrd patients
by age, gender, race, ethnicity, & primary diagnosis

table i.2 · 493
incident patient counts: aged 65 & over
esrd patients aged 65 & over, on day 1, by age, gender, race, ethnicity & primary diagnosis

table i.3 · 494
incident patient counts: dialysis patients
dialysis patients alive on day 91 by age, gender, race, ethnicity, & primary diagnosis

table i.4 · 495
patient counts: first transplant patients (cadaveric donor)
by age, gender, race, ethnicity, & primary diagnosis

table i.5 · 496
patient counts: first transplant patients (living donor)
by age, gender, race, ethnicity, & primary diagnosis

table i.6 · 497
one-year survival probabilities: incident esrd patients, unadjusted
from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.7 · 497
one-year survival probabilities: incident esrd patients, adjusted
from day 91 to one year + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.8 · 498
two-year survival probabilities: incident esrd patients, unadjusted
from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.9 · 498
two-year survival probabilities: incident esrd patients, adjusted
from day 91 to two years + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.10 · 499
five-year survival probabilities: incident esrd patients, unadjusted
from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.11 · 499
five-year survival probabilities: incident esrd patients, adjusted
from day 91 to five years + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.12 · 500
ten-year survival probabilities: incident esrd patients, unadjusted
from day 91 to ten years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.13 · 500
ten-year survival probabilities: incident esrd patients, adjusted
from day 91 to ten years + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.14 · 501
one-year survival probabilities: incident esrd patients aged 65 & over, unadjusted
from day 1 to one year, by age, gender, race, & ethnicity, & primary diagnosis

table i.15 · 501
one-year survival probabilities: incident esrd patients aged 65 & over, adjusted
from day 1 to one year, adjusted for age, gender, race, & primary diagnosis

table i.16 · 502
two-year survival probabilities: incident esrd patients aged 65 & over, unadjusted
from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis

table i.17 · 502
two-year survival probabilities: incident esrd patients aged 65 & over, adjusted
from day 1 to two years, adjusted for age, gender, race, & primary diagnosis

table i.18 · 503
five-year survival probabilities: incident esrd patients aged 65 & over, unadjusted
from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis

table i.19 · 503
five-year survival probabilities: incident esrd patients, adjusted
from day 1 to five years, adjusted for age, gender, race, & primary diagnosis

table i.20 · 504
ten-year survival probabilities: incident esrd patients aged 65 & over, unadjusted
from day 1 to ten years, by age, gender, race, ethnicity, & primary diagnosis

table i.21 · 504
ten-year survival probabilities: incident esrd patients, adjusted
from day 1 to ten years, adjusted for age, gender, race, & primary diagnosis

table i.22 · 505
one-year survival probabilities: incident dialysis patients, unadjusted
censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.23 · 505
one-year survival probabilities: incident dialysis patients, adjusted
censored at transplant, from day 91 to one year + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.24 · 506
two-year survival probabilities: incident dialysis patients, unadjusted
censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.25 · 506
two-year survival probabilities: incident dialysis patients, adjusted
censored at transplant, from day 91 to two years + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.26 · 507
five-year survival probabilities: incident dialysis patients, unadjusted
censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.27 · 507
five-year survival probabilities: incident dialysis patients, adjusted
censored at transplant, from day 91 to five years + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.28 · 508

ten-year survival probabilities: incident dialysis patients, unadjusted
censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis

table i.29 · 508

ten-year survival probabilities: incident dialysis patients, adjusted
censored at transplant, from day 91 to ten years + 90 days, adjusted for age, gender, race, & primary diagnosis

table i.30 · 509

one-year survival probabilities: first transplant patients (cadaveric donor), unadjusted
from day of transplant to one year, by age, gender, race, ethnicity, & primary diagnosis

table i.31 · 509

one-year survival probabilities: first transplant patients (cadaveric donor), adjusted
from day of transplant to one year, adjusted for age, gender, race, & primary diagnosis

table i.32 · 510

two-year survival probabilities: first transplant patients (cadaveric donor), unadjusted
from day of transplant to two years, by age, gender, race, ethnicity, & primary diagnosis

table i.33 · 510

two-year survival probabilities: first transplant patients (cadaveric donor), adjusted
from day of transplant to two years, adjusted for age, gender, race, & primary diagnosis

table i.34 · 511

five-year survival probabilities: first transplant patients (cadaveric donor), unadjusted
from day of transplant to five years, by age, race, gender, ethnicity, & primary diagnosis

table i.35 · 511

five-year survival probabilities: first transplant patients (cadaveric donor), adjusted
from day of transplant to five years, adjusted for age, gender, race, & primary diagnosis

table i.36 · 512

ten-year survival probabilities: first transplant patients (cadaveric donor), unadjusted
from day of transplant to ten years, by age, race, gender, ethnicity, & primary diagnosis

table i.37 · 512

ten-year survival probabilities: first transplant patients (cadaveric donor), adjusted
from day of transplant to ten years, adjusted for age, gender, race, & primary diagnosis

table i.38 · 513

one-year survival probabilities: first transplant patients (living donor), unadjusted
from day of transplant to one year, by age, gender, race, ethnicity, & primary diagnosis

table i.39 · 513

one-year survival probabilities: first transplant patients (living donor), adjusted
from day of transplant to one year, adjusted for age, gender, race, & primary diagnosis

table i.40 · 514

two-year survival probabilities: first transplant patients (living donor), unadjusted
from day of transplant to two years, by age, gender, race, ethnicity, & primary diagnosis

table i.41 · 514

two-year survival probabilities: first transplant patients (living donor), adjusted
from day of transplant to two years, adjusted for age, gender, race, & primary diagnosis

table i.42 · 515

five-year survival probabilities: first transplant patients (living donor), unadjusted
from day of transplant to five years, by age, gender, race, ethnicity, & primary diagnosis

table i.43 · 515

five-year survival probabilities: first transplant patients (living donor), adjusted
from day of transplant to five years, adjusted for age, gender, race, & primary diagnosis

table i.44 · 516

ten-year survival probabilities: first transplant patients (living donor), unadjusted
from day of transplant to ten years, by age, gender, race, ethnicity, & primary diagnosis

table i.45 · 516

ten-year survival probabilities: first transplant patients (living donor), adjusted
from day of transplant to ten years, adjusted for age, gender, race, & primary diagnosis

Table I.1
Incident Patient Counts: ESRD Patients
by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989
0-4	40	66	94	101	100	122	112	119	126	132
5-9	87	97	100	89	105	97	112	99	95	118
10-14	170	181	210	203	216	195	189	213	216	199
15-19	411	466	448	428	410	405	420	455	459	499
20-29	1,444	1,633	1,848	1,766	1,884	1,962	2,015	2,016	2,131	2,299
30-39	2,087	2,411	2,647	2,747	2,911	3,116	3,416	3,449	3,845	4,196
40-49	2,292	2,623	2,760	3,075	3,180	3,479	3,736	4,147	4,513	5,184
50-59	3,500	4,130	4,452	4,567	4,804	5,100	5,352	5,751	6,439	6,947
60-64	1,949	2,245	2,567	2,999	3,281	3,592	3,750	4,239	4,593	5,037
65-69	1,938	1,972	2,273	3,061	3,095	3,521	4,033	4,594	5,107	5,919
70-79	2,147	2,313	2,891	4,160	4,279	4,975	5,728	6,539	7,204	8,547
80+	339	346	497	826	881	1,117	1,366	1,603	1,946	2,401
Male	9,152	10,218	11,448	13,185	13,886	15,052	16,529	17,965	19,785	22,458
Female	7,252	8,265	9,339	10,837	11,260	12,629	13,700	15,259	16,889	19,020
White	10,112	11,727	13,953	15,693	16,508	18,166	19,838	21,564	23,688	26,817
Black	5,617	6,004	6,152	7,378	7,489	8,246	8,875	9,944	11,170	13,049
Other	675	752	682	951	1,149	1,269	1,516	1,716	1,816	1,612
†Hispanic										
†Non-Hispanic										
Diabetes	2,185	3,482	4,814	5,614	6,787	7,832	9,040	10,120	11,403	13,879
Hypertension	2,474	3,823	5,155	5,602	6,261	7,180	7,812	8,878	10,038	11,865
Glomerulonephritis	2,111	3,033	3,790	3,977	4,203	4,413	4,497	4,782	5,089	5,446
Cystic kidney	619	847	1,009	1,048	1,080	1,136	1,224	1,257	1,251	1,258
Other urologic	256	375	393	469	466	593	601	607	666	734
Other cause	1,554	2,192	2,983	3,336	3,563	3,882	3,960	4,104	4,172	4,611
Unknown cause	1,290	1,482	1,273	1,273	1,309	1,313	1,552	1,802	1,783	1,650
Missing cause	5,915	3,249	1,370	2,703	1,477	1,332	1,543	1,674	2,272	2,035
All	16,404	18,483	20,787	24,022	25,146	27,681	30,229	33,224	36,674	41,478

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	117	157	141	161	128	175	196	193	186	195
5-9	140	131	117	136	156	155	150	138	141	173
10-14	214	243	234	238	253	288	285	291	282	306
15-19	481	462	479	501	523	578	596	551	543	604
20-29	2,346	2,414	2,497	2,489	2,639	2,690	2,721	2,647	2,767	2,650
30-39	4,372	4,640	4,938	4,898	5,481	5,788	5,744	5,702	5,805	5,899
40-49	5,620	6,376	6,845	7,047	7,942	8,954	9,495	9,469	10,279	10,518
50-59	7,462	8,063	8,988	9,194	10,930	11,787	12,257	13,343	14,525	15,583
60-64	5,396	6,010	6,316	6,484	7,265	7,838	8,035	8,427	8,948	9,183
65-69	6,565	7,316	7,873	8,194	8,936	8,910	9,522	9,886	10,145	10,285
70-79	9,544	11,261	12,542	13,130	14,892	15,192	16,898	18,116	19,136	20,374
80+	2,792	3,263	3,821	4,129	4,706	5,124	6,023	6,882	7,559	8,467
Male	24,330	26,999	29,033	30,252	33,820	35,621	38,391	40,210	42,675	45,065
Female	20,719	23,337	25,758	26,349	30,031	31,858	33,531	35,435	37,641	39,172
White	29,237	32,600	35,202	35,642	39,750	40,924	43,310	47,229	49,746	53,214
Black	13,853	15,521	17,021	18,055	20,316	21,531	22,885	23,169	24,746	25,270
Other	1,959	2,215	2,568	2,904	3,785	5,024	5,727	5,247	5,824	5,753
†Hispanic							8,511	8,561	9,450	9,791
†Non-Hispanic							63,411	67,084	70,866	74,446
Diabetes	15,600	18,180	20,197	20,036	23,963	27,213	30,656	33,070	35,284	36,989
Hypertension	12,814	14,496	16,198	15,482	18,184	16,803	18,116	19,395	20,577	21,669
Glomerulonephritis	5,731	6,075	6,326	6,211	6,938	7,411	7,899	7,863	8,004	7,942
Cystic kidney	1,422	1,507	1,585	1,544	1,697	1,853	1,830	1,918	2,113	2,112
Other urologic	776	1,053	1,096	967	1,047	1,246	1,466	1,398	1,444	1,555
Other cause	4,491	4,711	4,979	4,913	5,686	7,292	7,661	7,981	8,511	8,921
Unknown cause	1,739	2,094	2,293	2,053	2,232	2,332	2,685	2,808	3,056	3,085
Missing cause	2,476	2,220	2,117	5,395	4,104	3,329	1,609	1,212	1,327	1,964
All	45,049	50,336	54,791	56,601	63,851	67,479	71,922	75,645	80,316	84,237

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Unknown age, gender, other & unknown are excluded. †CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table I.2

Incident Patient Counts: ESRD Patients Aged 65 & Over*esrd patients aged 65 & over, on day 1, by age, gender, race, ethnicity & primary diagnosis*

	1980-81	1982-83	1984-85	1986-87	1988-89	1990-81	1992-93	1994-95	1996-97	1998-99
65-69	4,316	5,882	7,356	9,446	11,967	15,053	17,337	19,268	21,012	22,131
70-74	3,235	4,989	6,346	8,085	10,156	13,371	16,517	19,125	21,819	23,495
75-79	1,861	3,025	4,252	5,774	7,678	9,914	12,207	14,533	17,683	21,134
80-84	679	1,216	1,822	2,640	3,731	5,117	6,607	8,261	10,645	12,821
85+	144	358	582	900	1,393	2,058	2,738	3,453	4,830	6,665
Male	5,607	8,287	10,761	13,997	18,141	23,469	28,260	32,456	39,033	44,428
Female	4,628	7,183	9,597	12,848	16,784	22,044	27,146	32,184	36,956	41,818
White	6,883	11,165	14,646	19,280	25,264	32,869	39,536	45,924	53,904	62,167
Black	2,973	3,885	4,997	6,503	8,462	11,092	13,656	15,217	17,532	19,205
Other	379	420	715	1,062	1,199	1,552	2,214	3,499	4,553	4,874
†Hispanic									6,922	8,011
†Non-Hispanic									69,067	78,235
Diabetes	1,234	2,628	4,229	6,463	9,550	14,123	17,812	23,527	30,791	36,020
Hypertension	2,572	5,199	7,253	10,086	13,833	18,251	21,217	23,521	25,686	29,310
Glomerulonephritis	1,017	1,819	2,397	2,874	3,451	4,137	4,279	5,119	5,654	5,677
Cystic kidney	270	421	462	574	603	739	761	967	1,006	1,050
Other urologic	337	437	633	777	922	1,123	1,162	1,289	1,574	1,680
Other cause	978	1,953	2,602	3,140	3,518	3,655	3,975	5,286	6,905	7,824
Unknown cause	1,173	1,241	1,364	1,875	2,051	2,324	2,593	2,734	3,408	3,887
Missing cause	2,654	1,772	1,418	1,056	997	1,161	3,607	2,197	965	798
All	10,235	15,470	20,358	26,845	34,925	45,513	55,406	64,640	75,989	86,246

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender, other & unknown are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes patients from U.S. & territories only.

Table I.3

Incident Patient Counts: Dialysis Patients

dialysis patients alive on day 91 by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989
0-4	26	52	68	78	83	94	90	83	94	103
5-9	59	66	72	70	74	63	79	71	63	75
10-14	132	148	169	155	156	135	123	128	138	121
15-19	348	379	362	370	330	324	313	340	363	401
20-29	1,249	1,428	1,629	1,568	1,677	1,706	1,752	1,761	1,843	1,968
30-39	1,903	2,179	2,435	2,512	2,670	2,826	3,040	3,075	3,420	3,784
40-49	2,166	2,507	2,636	2,938	3,023	3,301	3,493	3,862	4,206	4,852
50-59	3,444	4,082	4,369	4,494	4,714	5,024	5,205	5,560	6,247	6,777
60-64	1,947	2,236	2,564	2,985	3,272	3,577	3,722	4,198	4,560	4,989
65-69	1,938	1,971	2,274	3,067	3,094	3,514	4,034	4,589	5,105	5,903
70-79	2,150	2,315	2,894	4,168	4,277	4,978	5,733	6,548	7,212	8,555
80+	338	347	497	827	883	1,120	1,364	1,610	1,949	2,407
Male	8,693	9,714	10,911	12,672	13,339	14,432	15,734	17,107	18,883	21,546
Female	7,007	7,996	9,058	10,560	10,914	12,230	13,214	14,718	16,317	18,389
White	9,559	11,117	13,308	15,084	15,816	17,344	18,811	20,461	22,506	25,553
Black	5,537	5,912	6,046	7,286	7,394	8,152	8,754	9,801	10,969	12,849
Other	604	681	615	862	1,043	1,166	1,383	1,563	1,725	1,533
†Hispanic										
†Non-Hispanic										
Diabetes	2,117	3,352	4,655	5,463	6,587	7,615	8,747	9,812	11,120	13,562
Hypertension	2,438	3,775	5,100	5,568	6,212	7,128	7,736	8,804	9,945	11,789
Glomerulonephritis	1,993	2,895	3,596	3,797	4,005	4,181	4,256	4,509	4,835	5,165
Cystic kidney	609	822	986	1,019	1,032	1,086	1,139	1,171	1,164	1,179
Other urologic	252	365	374	454	453	574	572	594	651	709
Other cause	1,448	2,077	2,876	3,217	3,399	3,714	3,770	3,891	3,976	4,404
Unknown cause	1,263	1,448	1,233	1,241	1,286	1,269	1,506	1,756	1,742	1,603
Missing cause	5,580	2,976	1,149	2,473	1,279	1,095	1,222	1,288	1,767	1,524
All	15,700	17,710	19,969	23,232	24,253	26,662	28,948	31,825	35,200	39,935
	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	82	114	98	103	97	140	142	149	154	147
5-9	90	66	56	70	108	97	102	91	98	119
10-14	138	155	157	155	179	197	208	219	203	225
15-19	361	341	396	366	391	453	484	449	457	486
20-29	2,013	2,078	2,174	2,133	2,350	2,422	2,508	2,415	2,525	2,391
30-39	3,892	4,115	4,421	4,370	4,972	5,281	5,307	5,278	5,329	5,480
40-49	5,185	5,880	6,361	6,584	7,443	8,468	8,995	8,991	9,734	9,941
50-59	7,228	7,821	8,709	8,887	10,617	11,480	11,933	12,960	14,087	15,143
60-64	5,353	5,950	6,239	6,402	7,184	7,745	7,949	8,319	8,838	9,059
65-69	6,549	7,294	7,852	8,156	8,907	8,874	9,489	9,831	10,088	10,215
70-79	9,546	11,279	12,558	13,129	14,898	15,195	16,908	18,126	19,152	20,362
80+	2,798	3,270	3,827	4,134	4,710	5,137	6,038	6,905	7,571	8,485
Male	23,271	25,837	27,945	29,038	32,677	34,483	37,256	39,064	41,472	43,787
Female	19,964	22,526	24,903	25,451	29,179	31,006	32,807	34,669	36,764	38,266
White	27,770	30,979	33,645	33,964	38,301	39,514	41,902	45,637	47,986	51,349
Black	13,645	15,300	16,778	17,788	19,918	21,077	22,535	22,957	24,540	25,050
Other	1,820	2,084	2,425	2,737	3,637	4,898	5,626	5,139	5,710	5,654
†Hispanic							8,409	8,476	9,326	9,695
†Non-Hispanic							61,654	65,257	68,910	72,358
Diabetes	15,277	17,818	19,858	19,691	23,595	26,837	30,220	32,658	34,900	36,589
Hypertension	12,718	14,396	16,062	15,387	18,077	16,711	18,027	19,308	20,466	21,571
Glomerulonephritis	5,425	5,782	6,004	5,891	6,612	7,027	7,549	7,486	7,592	7,523
Cystic kidney	1,281	1,361	1,432	1,418	1,575	1,676	1,650	1,738	1,854	1,895
Other urologic	747	1,005	1,056	917	1,003	1,190	1,400	1,332	1,377	1,500
Other cause	4,273	4,482	4,761	4,663	5,442	6,996	7,370	7,661	8,235	8,636
Unknown cause	1,684	2,033	2,244	1,983	2,172	2,274	2,620	2,742	3,006	3,057
Missing cause	1,830	1,486	1,431	4,539	3,380	2,778	1,227	808	806	1,282
All	43,235	48,363	52,848	54,489	61,856	65,489	70,063	73,733	78,236	82,053

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Unknown age, gender, other & unknown are excluded.

Includes U.S. & territories; no unknown or foreign states.

Table I.4

Patient Counts: First Transplant Patients (Cadaveric Donor)*by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989
0-17	206	197	229	234	243	273	266	267	275	229
18-29	653	697	745	796	853	876	969	915	846	964
30-44	975	1,106	1,296	1,504	1,688	1,708	1,989	2,059	2,351	2,325
45-54	514	491	617	693	803	845	1,050	1,105	1,407	1,335
55+	167	184	219	297	400	477	651	789	1,118	1,090
Male	1,595	1,742	1,965	2,240	2,508	2,607	3,124	3,178	3,646	3,610
Female	920	933	1,141	1,284	1,479	1,572	1,801	1,957	2,351	2,333
White	1,834	1,905	2,245	2,537	2,858	2,940	3,499	3,660	4,217	4,207
Black	549	578	736	832	941	1,038	1,166	1,187	1,419	1,389
Other	132	192	125	155	188	201	260	288	361	347
†Hispanic										
†Non-Hispanic										
Diabetes	232	310	451	542	703	804	1,042	1,090	1,235	1,354
Hypertension	249	284	400	480	516	613	725	777	992	925
Glomerulonephritis	634	677	852	980	1,113	1,097	1,289	1,357	1,477	1,443
Cystic kidney	116	134	174	202	279	291	350	409	548	500
Other urologic	26	29	43	49	45	51	80	63	71	61
Other cause	349	364	449	597	687	739	807	797	846	821
Unknown cause	197	195	209	203	208	206	205	209	259	243
Missing cause	712	682	528	471	436	378	427	433	569	596
All	2,515	2,675	3,106	3,524	3,987	4,179	4,925	5,135	5,997	5,943
	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-17	250	210	207	242	273	250	259	249	221	272
18-29	986	954	858	870	816	851	723	692	678	666
30-44	2,509	2,542	2,497	2,602	2,582	2,566	2,483	2,369	2,499	2,321
45-54	1,506	1,519	1,576	1,755	1,828	1,914	1,994	2,061	2,060	2,014
55+	1,324	1,395	1,445	1,638	1,723	1,813	1,984	2,083	2,310	2,397
Male	3,981	4,028	3,945	4,274	4,435	4,606	4,495	4,485	4,693	4,602
Female	2,594	2,592	2,638	2,833	2,787	2,788	2,948	2,969	3,075	3,068
White	4,615	4,668	4,571	4,980	4,720	4,864	4,835	4,839	5,076	4,980
Black	1,551	1,561	1,581	1,697	2,033	2,098	2,097	2,075	2,085	2,069
Other	409	391	431	430	469	432	511	540	607	621
†Hispanic							479	588	730	762
†Non-Hispanic							6,964	6,866	7,038	6,908
Diabetes	1,479	1,570	1,599	1,870	1,909	1,977	2,114	2,181	2,396	2,330
Hypertension	1,102	1,081	1,154	1,221	1,372	1,349	1,341	1,317	1,335	1,293
Glomerulonephritis	1,596	1,575	1,493	1,517	1,548	1,622	1,569	1,594	1,661	1,632
Cystic kidney	570	535	588	605	530	624	622	646	618	648
Other urologic	81	100	81	139	109	113	125	122	167	147
Other cause	828	809	815	831	799	846	834	811	857	871
Unknown cause	255	233	237	251	269	227	238	268	257	271
Missing cause	664	717	616	673	686	636	600	515	477	478
All	6,575	6,620	6,583	7,107	7,222	7,394	7,443	7,454	7,768	7,670

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. Age is as of the date of transplantation.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Unknown age, gender, other & unknown are excluded.

Table I.5
Patient Counts: First Transplant Patients (Living Donor)
by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989
0-17	110	132	158	186	232	211	222	256	247	260
18-29	337	360	510	531	479	545	606	544	506	492
30-44	323	427	529	590	664	772	1,006	895	623	638
45-54	100	140	207	225	258	396	462	457	203	231
55+	15	35	70	80	120	186	285	292	89	128
Male	520	661	946	977	1,089	1,280	1,559	1,476	1,024	1,017
Female	365	433	528	635	664	830	1,022	968	644	732
White	735	891	1,177	1,292	1,408	1,696	2,059	1,911	1,370	1,454
Black	103	123	218	245	248	297	353	356	217	220
Other	47	80	79	75	97	117	169	177	81	75
†Hispanic										
†Non-Hispanic										
Diabetes	87	126	231	258	302	419	524	480	329	335
Hypertension	58	92	151	159	184	233	284	286	147	162
Glomerulonephritis	248	317	462	493	550	617	730	693	503	521
Cystic kidney	31	40	62	84	101	130	178	190	65	70
Other urologic	*	18	27	31	27	48	37	42	31	38
Other cause	136	172	201	301	362	397	495	436	314	345
Unknown cause	60	76	92	96	74	89	105	100	53	74
Missing cause	256	253	248	190	153	177	228	217	226	204
All	885	1,094	1,474	1,612	1,753	2,110	2,581	2,444	1,668	1,749
	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-17	254	319	282	352	262	350	343	323	336	343
18-29	539	566	552	628	611	564	623	634	638	663
30-44	721	831	881	952	979	1,088	1,098	1,172	1,311	1,177
45-54	256	321	382	461	500	612	724	755	867	936
55+	144	185	276	314	327	440	536	672	766	867
Male	1,089	1,276	1,357	1,583	1,534	1,752	1,935	2,078	2,237	2,357
Female	825	946	1,016	1,124	1,145	1,302	1,389	1,478	1,681	1,629
White	1,599	1,813	1,911	2,139	2,036	2,312	2,492	2,741	3,075	3,069
Black	223	304	332	422	486	563	619	564	586	657
Other	92	105	130	146	157	179	213	251	257	260
†Hispanic							315	414	470	431
†Non-Hispanic							3,009	3,142	3,448	3,555
Diabetes	365	447	436	506	531	576	692	698	847	832
Hypertension	160	226	290	330	362	377	417	438	470	491
Glomerulonephritis	556	583	645	692	742	839	926	1,047	1,075	1,094
Cystic kidney	94	111	126	133	138	195	225	238	316	298
Other urologic	45	60	76	93	80	99	114	122	115	126
Other cause	361	395	393	469	431	539	579	650	668	681
Unknown cause	81	83	101	126	109	122	132	147	187	140
Missing cause	252	317	306	358	286	307	239	216	240	324
All	1,914	2,222	2,373	2,707	2,679	3,054	3,324	3,556	3,918	3,986

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. Age is as of the date of transplantation.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Unknown age, gender, other & unknown are excluded.

Table I.6

One-year Survival Probabilities: Incident ESRD Patients, Unadjusted*from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	85.6	90.6	87.9	91.5	90.1	93.0	93.1	92.4	92.2	92.5	90.8
5-9	98.3	97.9	98.5	98.3	97.1	100.0	98.1	96.7	96.4	100.0	96.5
10-14	95.5	97.7	97.5	95.7	95.8	99.6	97.9	96.8	98.3	98.2	98.0
15-19	98.6	97.7	96.5	97.1	97.0	96.4	97.2	97.5	98.4	97.1	98.2
20-29	93.1	93.6	93.3	94.6	94.0	94.1	93.3	94.6	95.8	95.8	95.8
30-39	90.1	90.9	90.2	90.9	90.6	90.7	89.6	90.8	91.8	92.0	91.6
40-49	88.7	89.6	88.6	89.0	89.7	89.4	89.7	90.0	90.7	89.7	90.3
50-59	83.4	84.5	84.6	85.5	85.4	86.2	86.3	86.0	86.5	86.3	86.6
60-64	78.3	78.9	79.5	80.0	81.5	81.6	80.8	82.0	82.6	81.0	81.9
65-69	73.9	75.6	75.1	75.6	77.3	76.5	77.3	77.7	76.7	76.1	76.5
70-79	67.3	68.4	68.2	68.4	70.0	70.1	70.3	70.6	69.5	69.6	69.3
80+	57.7	59.3	59.1	58.3	61.0	60.9	60.3	60.2	59.5	57.4	58.3
Male	78.6	79.5	79.0	79.0	80.3	80.0	80.2	80.3	80.0	79.5	79.7
Female	79.0	79.6	79.0	79.3	79.7	79.9	80.0	79.8	79.3	78.5	78.3
White	76.3	77.0	76.3	76.4	77.4	77.4	77.7	77.5	76.8	76.4	76.7
Black	82.9	83.8	83.3	83.7	83.8	83.9	83.5	83.8	84.2	83.0	82.9
Other race	86.0	86.9	87.9	86.3	88.1	86.4	85.1	84.4	85.5	84.7	84.5
†Hispanic								84.2	84.1	84.1	83.6
†Non-Hispanic								79.5	79.1	78.4	78.5
Diabetes	76.8	76.9	77.3	77.5	79.4	79.0	79.0	79.2	78.6	77.8	78.5
Hypertension	76.2	77.4	76.4	76.7	77.4	77.3	78.7	78.5	77.7	77.1	77.0
Glomerulonephritis	86.8	87.3	86.1	87.8	88.8	87.2	88.3	89.0	88.8	89.0	88.3
Other cause	80.3	81.8	81.2	80.7	79.8	81.5	79.6	79.0	79.9	79.4	78.7
All	78.8	79.6	79.0	79.2	80.0	80.0	80.1	80.1	79.7	79.1	79.1

Table I.7

One-year Survival Probabilities: Incident ESRD Patients, Adjusted*from day 91 to one year + 90 days, adjusted for age, gender, race, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-19	97.2	97.5	97.6	97.4	97.7	97.6	97.7	97.3	97.2	97.2	97.2
20-44	92.4	93.0	92.6	92.8	93.2	92.8	92.3	92.4	92.7	92.1	92.0
45-64	82.2	83.2	83.5	84.0	84.6	85.1	85.1	85.4	85.9	85.2	85.7
65-74	70.8	72.6	72.3	73.3	74.3	74.5	74.8	75.3	75.1	74.9	74.8
75+	60.8	62.2	62.7	62.5	64.1	64.7	64.2	65.2	64.9	63.8	63.6
Male	77.0	78.2	78.2	78.6	79.8	79.9	80.0	80.4	80.5	80.1	80.5
Female	77.9	79.1	79.1	79.6	80.1	80.5	80.4	80.7	80.9	80.2	80.1
White	76.3	77.3	77.3	77.8	78.7	78.9	78.9	79.3	79.2	78.8	79.3
Black	78.7	80.3	80.4	80.9	81.7	82.1	82.2	82.6	83.0	82.1	81.6
Other race	82.5	83.5	83.9	83.5	84.5	84.3	83.7	84.1	85.0	83.9	84.3
Diabetes	72.5	73.8	74.1	74.8	76.4	76.7	76.7	77.4	77.6	77.3	78.7
Hypertension	79.0	80.3	79.7	80.2	81.0	81.0	81.5	81.9	81.8	81.3	81.4
Glomerulonephritis	84.2	85.0	84.9	85.6	86.4	86.3	86.6	86.7	86.9	86.8	86.6
Other cause	81.7	82.9	83.0	82.8	82.5	83.0	82.1	82.1	82.2	80.9	79.2
All	77.5	78.6	78.6	79.1	80.0	80.2	80.2	80.6	80.7	80.1	80.3

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. Age as of date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.8

Two-year Survival Probabilities: Incident ESRD Patients, Unadjusted

from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-4	78.6	81.8	86.3	85.4	91.5	87.6	87.5	90.3	88.8	89.6	88.2
5-9	96.8	97.5	95.0	98.5	98.3	93.4	97.4	96.8	96.0	95.7	97.9
10-14	95.8	94.0	95.3	96.7	94.4	94.1	98.4	95.8	95.8	96.6	97.5
15-19	95.4	97.0	95.6	94.2	95.6	94.8	94.8	95.5	94.1	95.6	95.2
20-29	88.5	88.9	88.6	88.3	90.0	90.1	90.3	89.0	90.8	91.9	92.6
30-39	83.0	82.7	83.2	82.4	83.2	84.1	83.4	83.2	84.1	85.5	85.5
40-49	78.9	78.4	80.6	78.4	80.0	80.1	80.4	81.0	81.3	82.3	81.7
50-59	69.6	70.6	71.0	71.5	72.3	73.1	74.6	74.2	74.3	75.1	74.4
60-64	60.5	62.0	62.3	63.5	64.0	65.8	66.6	65.8	67.6	68.0	66.8
65-69	56.1	56.1	56.7	57.0	58.1	60.1	59.1	60.2	60.8	59.3	59.7
70-79	46.4	47.7	48.0	48.2	49.1	50.2	50.4	51.0	51.5	49.7	50.8
80+	33.1	37.3	36.6	36.1	36.7	37.6	38.6	38.6	38.5	37.2	37.2
Male	64.0	64.5	64.7	64.2	64.6	65.9	65.9	66.6	66.4	65.8	65.9
Female	64.7	64.8	64.6	63.9	64.8	64.8	65.5	65.5	65.7	64.7	64.5
White	60.8	61.1	61.1	60.3	60.8	61.3	61.6	62.1	61.9	60.9	61.2
Black	70.8	70.5	70.8	70.0	71.0	71.6	72.0	72.0	72.2	72.3	71.3
Other race	70.0	74.7	74.7	77.8	75.6	77.4	75.1	73.4	73.2	74.4	73.5
†Hispanic									71.7	71.6	71.9
†Non-Hispanic									65.3	64.5	64.3
Diabetes	57.9	59.4	58.6	59.4	60.2	62.2	61.8	62.3	62.8	61.9	61.6
Hypertension	60.8	61.3	61.4	60.5	61.6	62.2	62.6	64.3	64.1	62.7	62.6
Glomerulonephritis	77.7	76.7	77.5	75.9	78.1	79.5	78.0	79.4	79.9	79.7	80.8
Other cause	68.3	69.1	70.4	69.6	69.2	67.2	70.1	68.2	67.9	68.7	68.7
All	64.3	64.6	64.6	64.1	64.7	65.4	65.7	66.1	66.1	65.3	65.2

Table I.9

Two-year Survival Probabilities: Incident ESRD Patients, Adjusted

from day 91 to two years + 90 days, adjusted for age, gender, race, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-19	94.1	94.8	95.2	95.3	95.1	95.6	95.4	95.6	94.9	94.7	94.9
20-44	85.6	86.2	86.7	86.1	86.6	87.0	86.5	85.7	85.9	86.2	85.7
45-64	67.7	69.1	69.7	70.4	71.4	72.1	73.1	73.3	73.8	74.5	74.0
65-74	50.8	52.3	53.4	53.3	55.0	55.9	56.6	57.3	58.1	57.4	58.2
75+	36.3	39.4	39.5	40.6	40.8	42.1	43.2	42.9	44.1	43.4	43.1
Male	60.1	62.2	62.8	63.1	64.0	65.3	65.7	66.0	66.7	66.5	66.7
Female	62.5	63.5	64.0	64.4	65.5	65.8	66.6	66.6	67.2	67.2	66.9
White	59.5	61.2	61.4	61.7	62.7	63.5	64.1	64.3	64.9	64.5	64.8
Black	63.7	64.6	65.8	66.2	67.3	68.1	69.0	69.2	70.0	70.4	69.7
Other race	66.7	70.1	70.8	71.6	71.3	72.5	72.4	71.5	72.3	73.4	72.4
Diabetes	54.0	55.9	56.4	57.2	58.5	60.2	61.0	61.1	62.2	62.3	62.8
Hypertension	63.6	65.0	65.7	65.2	66.3	67.0	67.3	68.3	68.9	68.5	68.5
Glomerulonephritis	72.3	72.8	73.1	73.2	74.6	75.6	75.5	76.2	76.5	76.6	77.0
Other cause	67.4	69.0	69.7	70.1	70.1	69.3	70.4	69.1	69.1	69.1	67.9
All	61.3	62.8	63.4	63.7	64.7	65.5	66.1	66.3	66.9	66.9	66.8

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

Age as of date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table I.10

Five-year Survival Probabilities: Incident ESRD Patients, Unadjusted*from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-4	80.3	82.1	79.8	76.2	78.8	83.8	83.4	87.2	83.2	84.4	85.7
5-9	87.6	91.1	95.0	93.7	94.9	91.4	96.2	94.0	90.4	94.9	94.8
10-14	91.8	91.5	95.3	92.6	88.9	91.1	92.2	88.5	89.9	94.1	93.4
15-19	85.4	88.1	87.9	88.2	90.2	90.6	88.3	91.4	90.0	89.5	90.8
20-29	76.2	78.8	76.5	79.1	78.3	79.3	79.7	80.3	81.1	82.3	80.5
30-39	64.4	66.5	63.6	67.9	68.5	68.6	67.3	67.6	69.8	69.2	69.7
40-49	56.4	57.2	58.1	58.5	57.2	58.8	57.7	59.4	60.1	60.1	61.6
50-59	39.2	41.2	42.5	41.6	42.1	42.0	44.0	43.4	45.5	46.8	47.3
60-64	27.9	29.4	28.5	30.5	30.7	31.1	31.2	32.1	33.1	34.7	35.0
65-69	22.7	22.4	23.3	23.2	23.5	23.5	22.9	24.6	25.2	26.3	26.4
70-79	15.5	14.9	15.5	15.6	16.2	15.8	16.1	16.1	16.9	17.2	17.9
80+	8.3	7.7	7.7	6.7	8.9	8.6	7.6	7.7	8.2	8.5	9.5
Male	39.0	39.7	38.9	39.1	39.3	38.9	38.3	37.9	39.3	39.4	41.0
Female	39.4	39.0	38.1	38.5	37.4	37.0	36.2	36.7	36.7	37.6	37.9
White	37.4	37.1	35.9	35.5	35.2	34.5	33.7	33.6	34.2	34.1	34.7
Black	42.1	42.9	42.4	44.5	43.4	43.7	42.9	43.4	43.6	45.2	46.8
Other race	45.2	48.3	48.8	47.5	51.7	50.5	51.2	48.7	50.5	50.4	47.9
†Hispanic											
†Non-Hispanic											
Diabetes	26.6	28.5	27.5	28.4	28.5	27.7	28.2	28.8	30.1	30.4	30.9
Hypertension	35.7	34.4	32.8	33.8	33.7	33.9	32.3	33.2	33.8	33.7	36.5
Glomerulonephritis	55.7	56.5	56.0	57.5	57.0	56.6	55.8	57.0	59.2	57.8	59.9
Other cause	45.2	46.2	46.8	46.2	47.4	47.8	48.2	46.9	44.4	48.8	47.9
All	39.2	39.4	38.5	38.8	38.4	38.0	37.3	37.4	38.1	38.6	39.5

Table I.11

Five-year Survival Probabilities: Incident ESRD Patients: Adjusted*from day 91 to five years + 90 days, adjusted for age, gender, race, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-19	84.1	86.6	86.5	86.5	87.7	88.4	88.8	88.0	89.2	88.9	89.5
20-44	66.2	68.1	66.7	69.0	69.6	70.1	69.0	69.4	70.3	69.4	68.1
45-64	36.1	38.4	38.9	39.7	41.0	41.1	42.4	43.1	43.9	45.6	46.5
65-74	18.8	19.2	19.9	20.5	21.3	21.7	21.9	22.8	23.5	24.3	25.6
75+	10.1	10.2	10.0	9.7	11.2	10.8	11.6	11.2	11.9	12.7	12.9
Male	32.0	33.6	33.6	34.3	35.8	36.0	36.5	36.8	38.2	38.7	39.4
Female	34.6	35.6	35.7	36.8	37.2	37.4	37.9	38.5	38.7	39.8	40.1
White	32.0	32.9	32.9	33.4	34.5	34.3	34.6	35.2	35.9	36.6	37.1
Black	34.6	36.1	36.3	37.9	38.3	39.2	39.8	40.5	41.2	42.5	43.2
Other race	37.5	41.2	41.0	41.5	45.1	45.4	46.6	45.6	47.1	47.1	46.3
Diabetes	24.5	26.2	26.4	27.6	28.9	28.9	29.8	30.5	32.2	33.0	33.6
Hypertension	36.7	37.2	36.6	37.6	38.5	38.9	38.4	39.1	39.9	40.3	42.0
Glomerulonephritis	45.9	47.3	47.4	48.5	48.6	48.4	48.8	50.2	51.5	51.6	53.0
Other cause	39.9	41.8	42.0	42.1	43.4	43.8	44.6	43.9	42.7	44.3	43.0
All	33.2	34.5	34.6	35.4	36.5	36.7	37.1	37.6	38.4	39.2	39.7

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

Age as of date of ESRD initiation.

Includes U.S. & territories; no unknown or foreign states.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table I.12

Ten-year Survival Probabilities: Incident ESRD Patients, Unadjusted

from day 91 to ten years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	75.0	69.7	77.7	75.3	71.0	73.0	79.5	79.0	67.5	76.5	77.8
5-9	81.6	81.4	78.0	82.0	84.8	81.4	85.7	82.8	91.6	89.0	87.1
10-14	78.2	77.4	77.6	83.3	82.4	83.1	85.2	87.8	84.7	80.4	83.2
15-19	79.6	80.0	79.7	80.4	78.5	76.3	78.8	78.5	79.3	83.6	83.6
20-29	64.4	62.7	65.9	63.4	63.9	64.7	65.4	64.6	67.7	65.3	67.4
30-39	47.3	47.5	48.2	49.2	48.9	47.2	49.7	47.7	49.5	50.6	52.0
40-49	32.4	32.9	33.7	33.8	35.7	35.7	36.5	36.0	36.3	35.0	36.3
50-59	15.9	18.0	18.1	16.7	17.1	17.7	18.3	19.6	18.0	18.3	18.8
60-64	8.2	8.6	6.7	8.8	8.3	9.2	9.0	8.5	9.1	8.9	8.7
65-69	4.5	5.0	4.0	4.8	5.2	6.2	5.1	4.8	5.0	4.8	5.3
70-79	2.4	2.0	2.8	2.1	2.9	2.7	2.2	2.6	2.3	2.1	2.1
80+	1.2	0.6	1.6	0.2	1.3	0.8	0.7	0.6	0.4	0.6	0.3
Male	24.9	25.7	26.1	23.4	23.7	23.0	23.4	22.3	21.8	21.3	21.7
Female	24.9	25.8	24.3	21.7	22.5	21.8	20.8	20.0	20.1	19.1	18.5
White	26.1	26.3	25.6	22.8	23.1	22.4	21.9	21.0	20.0	19.3	19.3
Black	22.0	23.9	23.3	20.8	21.9	21.5	21.1	20.2	21.9	21.1	20.7
Other race	30.5	32.1	35.6	33.8	31.9	29.7	32.1	30.1	29.2	29.8	30.8
†Hispanic											
†Non-Hispanic											
Diabetes	11.7	11.7	11.6	11.1	11.7	12.0	12.2	11.6	11.3	11.1	10.3
Hypertension	22.0	19.4	18.5	17.0	17.3	16.4	16.2	14.3	14.9	14.7	14.8
Glomerulonephritis	46.1	42.4	42.5	40.2	40.3	39.4	40.0	38.5	39.2	38.6	38.8
Other cause	23.9	28.5	30.3	25.6	28.4	28.6	28.6	29.2	28.8	29.4	31.1
All	24.9	25.7	25.3	22.6	23.1	22.4	22.2	21.2	21.0	20.3	20.2

Table I.13

Ten-year Survival Probabilities: Incident ESRD Patients, Adjusted

from day 91 to ten years + 90 days, adjusted for age, gender, race, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-19	73.5	71.8	71.4	74.0	74.1	72.8	76.0	75.7	75.1	76.9	78.2
20-44	45.0	44.5	46.3	46.6	46.8	47.2	48.3	46.4	48.4	48.5	49.5
45-64	14.5	14.4	14.9	15.1	15.6	16.1	16.9	17.2	17.0	17.4	17.8
65-74	4.0	4.0	4.5	3.8	4.9	5.2	4.9	5.2	5.1	5.1	5.4
75+	1.3	1.2	1.4	0.9	1.6	1.8	1.6	1.6	1.3	1.6	1.5
Male	15.3	15.4	16.2	15.9	16.5	16.8	17.5	17.3	17.4	18.0	18.4
Female	17.3	17.0	17.7	17.7	18.4	18.7	18.9	18.8	19.2	19.0	19.4
White	16.0	15.7	16.0	15.9	16.3	16.7	16.8	16.6	16.6	16.9	17.0
Black	15.8	16.3	17.2	17.0	18.3	18.5	19.2	19.1	19.8	19.5	20.5
Other race	19.1	18.0	21.4	21.3	20.4	20.7	23.0	22.7	22.6	24.9	25.5
Diabetes	9.6	9.2	9.6	10.3	10.6	11.2	11.9	11.8	12.3	12.7	13.0
Hypertension	20.1	18.9	19.2	19.2	18.8	19.6	19.4	18.8	19.1	19.3	19.9
Glomerulonephritis	27.1	26.0	26.8	26.3	27.6	27.2	27.7	27.6	28.1	27.5	27.7
Other cause	18.2	20.1	21.8	20.4	22.4	22.1	23.0	23.0	22.6	23.1	23.8
All	16.2	16.1	16.8	16.7	17.3	17.6	18.1	18.0	18.2	18.4	18.9

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

Age as of date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Table I.14

One-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Unadjusted*from day 1 to one year, by age, gender, race, ethnicity, & primary diagnosis*

	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	74.0	75.4	75.8	75.3	75.0
70-74	68.3	70.2	70.3	69.7	69.5
75-79	63.8	63.6	64.6	64.1	63.1
80-84	57.7	59.3	59.0	58.6	56.6
85+	51.2	51.1	52.2	49.0	47.6
Male	65.9	67.2	67.3	66.3	65.5
Female	68.6	69.0	69.2	67.9	66.0
White	64.4	65.2	65.7	64.8	63.7
Black	74.2	74.9	74.5	72.6	70.5
Other race	77.1	77.6	75.3	73.5	72.4
†Hispanic				71.5	71.1
†Non-Hispanic				66.7	65.2
Diabetes	68.3	70.0	69.9	69.2	67.9
Hypertension	65.6	65.7	66.9	66.2	65.0
Glomerulonephritis	72.8	74.9	74.1	74.3	73.5
Other cause	66.4	67.1	65.3	61.2	59.2
All	67.2	68.1	68.3	67.1	65.7

Table I.15

One-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Adjusted*from day 1 to one year, adjusted for age, gender, race, & primary diagnosis*

	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	73.2	74.4	74.9	74.6	74.3
70-74	68.4	69.8	70.4	69.7	69.5
75-79	64.0	64.5	65.1	64.9	63.8
80-84	57.8	58.9	59.6	58.9	57.4
85+	50.2	52.1	52.2	50.5	48.4
Male	65.8	66.9	67.6	67.2	66.9
Female	67.3	68.5	68.9	68.2	67.0
White	64.2	65.6	66.2	65.7	65.4
Black	71.9	72.5	73.2	72.3	70.8
Other race	73.8	74.0	73.7	73.8	72.2
Diabetes	62.4	64.2	65.2	64.9	65.3
Hypertension	67.0	68.0	68.7	68.8	68.1
Glomerulonephritis	73.0	74.3	74.4	74.1	74.0
Other cause	70.3	70.5	70.1	67.8	64.9
All	66.5	67.7	68.2	67.7	67.0

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

Age as of date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.16

Two-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Unadjusted

from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis

	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	55.4	56.2	58.3	59.0	59.0	58.6
70-74	48.1	49.3	51.1	52.0	51.6	52.1
75-79	41.7	43.7	44.5	45.3	44.9	44.5
80-84	35.6	36.6	38.1	38.9	38.2	37.0
85+	28.6	28.4	29.4	30.5	29.4	28.2
Male	45.3	46.7	48.0	48.7	47.9	47.6
Female	49.0	49.3	50.7	50.9	49.7	48.0
White	43.8	44.5	45.6	46.5	45.7	45.2
Black	55.8	56.4	57.9	57.7	56.0	53.9
Other race	54.1	61.0	61.9	58.1	57.3	56.5
†Hispanic					53.5	53.6
†Non-Hispanic					48.3	47.2
Diabetes	45.0	46.7	49.5	49.8	49.3	48.8
Hypertension	46.3	46.6	47.3	48.9	48.4	47.2
Glomerulonephritis	54.5	55.6	57.7	57.0	57.1	57.2
Other cause	47.7	49.3	49.5	48.3	45.0	43.3
All	47.1	48.0	49.3	49.7	48.8	47.8

Table I.17

Two-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Adjusted

from day 1 to two years, adjusted for age, gender, race, ethnicity, & primary diagnosis

	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	54.6	55.8	57.7	58.7	58.7	58.9
70-74	47.7	49.2	51.3	52.3	51.9	52.3
75-79	41.0	43.5	44.2	45.4	45.6	44.9
80-84	34.5	36.0	37.5	38.5	38.3	37.3
85+	26.8	27.8	29.8	30.3	29.0	27.6
Male	44.1	46.1	47.6	48.9	49.0	49.3
Female	46.7	48.0	49.8	50.6	50.2	49.4
White	42.7	44.0	45.9	47.0	46.9	47.3
Black	52.0	54.2	55.2	56.4	55.7	54.3
Other race	53.0	56.8	57.3	57.1	57.8	56.2
Diabetes	39.8	41.9	44.3	45.8	46.0	47.3
Hypertension	46.4	47.7	49.1	50.4	51.0	50.8
Glomerulonephritis	53.7	55.8	57.8	58.1	58.3	58.8
Other cause	50.5	52.0	52.4	52.2	49.7	46.7
All	45.4	47.1	48.7	49.7	49.6	49.4

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

Age as of date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.18

Five-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Unadjusted*from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis*

	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	22.5	23.2	23.2	24.7	26.1	26.7
70-74	16.5	17.5	17.7	18.9	19.6	19.8
75-79	12.6	12.5	12.8	12.7	14.0	15.2
80-84	7.9	8.4	8.9	8.8	9.4	9.6
85+	5.0	5.5	5.1	5.4	6.4	5.9
Male	14.9	16.0	16.1	16.3	17.3	17.6
Female	18.3	17.9	17.7	18.7	19.2	19.1
White	14.3	14.7	14.3	14.9	15.5	15.8
Black	22.5	22.8	23.5	23.7	24.9	23.7
Other race	19.3	22.9	25.6	25.2	25.4	27.2
†Hispanic						21.4
†Non-Hispanic						18.0
Diabetes	12.3	12.9	13.7	15.2	16.2	16.6
Hypertension	16.1	16.5	16.3	16.5	17.8	18.2
Glomerulonephritis	21.5	22.9	23.1	24.3	24.8	25.2
Other cause	18.8	19.7	20.1	20.1	20.3	19.7
All	16.5	16.9	16.9	17.5	18.3	18.3

Table I.19

Five-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Adjusted*from day 1 to five years, adjusted for age, gender, race, & primary diagnosis*

	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	21.2	23.1	23.5	24.8	26.3	27.3
70-74	15.8	16.8	17.3	18.4	19.8	20.3
75-79	11.3	11.7	12.8	12.8	13.9	14.9
80-84	7.2	7.8	8.1	8.5	9.3	9.8
85+	4.0	4.4	4.4	4.9	5.2	5.1
Male	13.5	14.6	15.5	16.1	17.5	18.4
Female	15.7	16.6	16.9	17.9	19.0	19.5
White	12.5	13.3	13.5	14.5	15.7	16.5
Black	19.8	21.0	22.2	22.6	24.3	24.6
Other race	18.7	22.0	24.8	24.8	25.0	26.8
Diabetes	10.6	11.5	12.3	13.5	15.0	16.0
Hypertension	15.4	16.4	16.6	17.3	18.8	20.3
Glomerulonephritis	22.1	22.9	24.1	25.5	26.4	27.6
Other cause	18.5	19.9	20.4	20.2	20.4	19.1
All	14.6	15.6	16.2	17.0	18.2	19.0

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule. Age as of date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.20

Ten-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Unadjusted

from day 1 to ten years, by age, gender, race, ethnicity, & primary diagnosis

	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91
65-69	4.8	4.4	5.7	4.9	4.8	5.1
70-74	2.6	2.9	3.1	2.8	2.6	2.5
75-79	1.5	1.4	1.7	1.8	1.4	1.3
80-84	0.9	0.9	1.0	0.8	0.6	0.6
85+	0.7	.	0.5	0.2	0.4	0.3
Male	2.8	2.3	3.2	3.0	2.5	2.6
Female	3.7	3.7	3.8	3.1	3.1	3.0
White	2.9	2.5	3.2	2.7	2.3	2.2
Black	4.0	3.9	4.3	3.8	4.1	4.0
Other race	1.9	4.3	3.5	4.9	4.7	5.5
†Hispanic						
†Non-Hispanic						
Diabetes	1.9	1.8	2.3	1.6	1.6	1.6
Hypertension	2.8	2.6	3.0	2.6	2.4	2.4
Glomerulonephritis	3.7	4.3	4.8	4.9	4.7	4.6
Other cause	3.6	3.4	4.4	4.1	4.2	4.5
All	3.2	2.9	3.5	3.1	2.8	2.8

Table I.21

Ten-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over, Adjusted

from day 1 to ten years, adjusted for age, gender, race, & primary diagnosis

	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91
65-69	4.1	3.9	4.9	4.6	4.7	4.8
70-74	2.3	2.4	2.9	2.6	2.5	2.6
75-79	1.2	1.0	1.6	1.4	1.2	1.4
80-84	0.4	0.5	0.8	0.6	0.5	0.6
85+	0.2	0.1	0.3	0.2	0.2	0.2
Male	1.8	1.6	2.3	2.2	2.1	2.4
Female	2.5	2.7	3.3	2.9	2.8	2.8
White	1.9	1.6	2.2	1.8	1.7	1.7
Black	2.8	3.3	4.4	4.3	4.2	4.5
Other race	2.0	2.8	3.2	3.9	4.5	5.6
Diabetes	1.0	1.0	1.7	1.4	1.4	1.5
Hypertension	2.9	2.7	3.2	2.7	2.6	2.7
Glomerulonephritis	4.4	5.1	5.5	5.4	5.0	5.5
Other cause	2.7	2.8	3.7	3.8	3.8	4.0
All	2.1	2.1	2.8	2.5	2.5	2.6

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule. Age as of date of ESRD initiation.
 Unknown age, gender; other & unknown, & primary diagnosis are excluded.
 †CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.
 Includes U.S. & territories; no unknown or foreign states.
 "." Zero values in this cell.

Table I.22

One-year Survival Probabilities: Incident Dialysis Patients, Unadjusted*censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	84.1	85.9	82.3	86.9	86.6	90.1	91.2	89.5	89.9	90.8	86.3
5-9	100.0	95.3	95.7	94.7	96.8	100.0	98.9	94.0	97.5	100.0	96.3
10-14	95.8	96.5	97.6	93.4	93.5	99.3	98.1	95.6	97.1	97.7	96.8
15-19	98.0	97.2	95.2	97.2	96.7	95.3	97.0	97.0	97.8	96.2	97.4
20-29	91.6	92.0	91.9	93.3	92.3	93.1	92.1	93.7	95.3	95.0	95.1
30-39	88.5	89.4	88.5	89.5	89.1	89.3	88.1	89.7	90.8	91.0	90.6
40-49	87.8	88.8	87.3	87.9	88.8	88.5	89.0	89.3	90.0	88.9	89.5
50-59	82.9	84.0	84.0	84.9	84.9	85.8	85.8	85.5	86.0	85.7	86.1
60-64	78.0	78.6	79.2	79.8	81.2	81.4	80.4	81.8	82.2	80.7	81.6
65-69	73.9	75.5	75.1	75.5	77.3	76.4	77.1	77.5	76.5	76.0	76.3
70-79	67.3	68.4	68.3	68.5	70.0	70.1	70.3	70.6	69.5	69.6	69.3
80+	57.8	59.4	59.2	58.4	61.0	60.9	60.4	60.3	59.6	57.4	58.4
Male	77.2	78.1	77.6	77.8	79.1	79.0	79.1	79.4	79.1	78.6	78.8
Female	77.9	78.6	77.8	78.3	78.7	79.1	79.2	79.2	78.6	77.8	77.6
White	74.5	75.2	74.4	74.8	75.8	76.0	76.4	76.3	75.5	75.1	75.4
Black	82.5	83.5	82.9	83.4	83.5	83.4	83.1	83.5	84.0	82.8	82.7
Other race	84.9	85.7	86.7	85.3	87.2	85.7	84.4	84.0	85.0	84.2	84.0
†Hispanic								83.9	83.7	83.7	83.2
†Non-Hispanic								78.6	78.2	77.4	77.6
Diabetes	75.8	76.1	76.5	76.8	78.9	78.4	78.5	78.7	78.1	77.4	78.1
Hypertension	75.8	77.0	76.0	76.3	77.0	77.0	78.4	78.2	77.4	76.8	76.7
Glomerulonephritis	85.2	85.9	84.6	86.5	87.5	86.1	87.1	87.9	87.7	88.0	87.4
Other cause	78.1	79.4	78.5	78.3	77.6	79.6	77.6	77.3	78.0	77.3	76.6
All	77.5	78.3	77.7	78.0	78.9	79.0	79.2	79.3	78.8	78.2	78.3

Table I.23

One-year Survival Probabilities: Incident Dialysis Patients, Adjusted*censored at transplant, from day 91 to one year + 90 days, adjusted for age, gender, race, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-19	95.2	94.8	94.7	94.8	95.2	95.5	96.2	95.6	95.9	95.5	95.5
20-44	88.3	89.3	88.5	89.1	89.7	89.7	89.7	90.3	90.8	90.5	90.8
45-64	80.6	81.7	81.9	82.1	83.1	83.7	83.9	84.3	84.9	84.3	85.0
65-74	72.5	74.1	73.6	74.6	75.4	75.4	75.4	75.7	75.3	74.9	74.7
75+	63.6	64.5	64.8	64.8	66.2	66.2	65.6	66.2	65.8	64.3	63.9
Male	76.1	77.2	77.2	77.5	78.8	79.0	79.1	79.5	79.6	79.2	79.7
Female	77.5	78.7	78.3	78.9	79.5	79.8	79.7	80.1	80.2	79.4	79.3
White	74.6	75.6	75.5	76.0	77.0	77.4	77.5	78.0	77.9	77.6	78.2
Black	80.0	81.5	81.2	81.7	82.4	82.5	82.4	82.7	83.0	81.9	81.3
Other race	82.1	83.1	83.1	83.2	84.2	84.1	83.4	83.9	84.7	83.4	83.8
Diabetes	72.1	73.4	73.7	74.2	75.9	76.1	76.2	76.8	77.0	76.7	78.1
Hypertension	78.8	79.8	79.2	79.7	80.4	80.5	81.1	81.4	81.3	80.7	80.8
Glomerulonephritis	82.4	83.6	83.3	84.2	85.1	85.0	85.3	85.6	85.7	85.8	85.8
Other cause	80.4	81.3	81.1	81.1	80.8	81.5	80.5	80.7	80.9	79.4	77.8
All	76.8	77.9	77.7	78.2	79.1	79.4	79.4	79.8	79.9	79.3	79.5

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender; other & unknown are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.24

Two-year Survival Probabilities: Incident Dialysis Patients, Unadjusted

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-4	71.3	79.3	78.4	78.4	86.9	85.1	82.7	87.6	85.3	86.6	83.8
5-9	100.0	96.7	87.8	95.7	94.7	86.3	96.0	96.6	92.3	97.5	94.9
10-14	94.5	95.8	89.3	96.4	90.8	90.5	95.7	94.4	93.3	93.4	95.9
15-19	94.8	95.7	94.3	91.9	95.0	92.6	93.4	94.2	91.3	93.4	93.0
20-29	84.7	84.9	84.1	84.3	86.6	86.7	87.6	86.2	88.4	89.9	90.9
30-39	79.0	78.4	78.8	77.9	79.3	80.4	80.0	80.1	81.4	83.1	82.9
40-49	75.9	75.4	78.4	74.7	77.0	77.0	77.9	79.0	79.4	80.3	79.7
50-59	67.8	69.0	69.3	69.5	70.5	71.5	73.1	72.7	73.0	73.5	72.8
60-64	59.7	61.1	61.3	62.8	63.1	65.0	65.9	64.8	66.8	67.1	65.8
65-69	56.0	55.9	56.4	56.7	57.9	59.8	58.9	59.8	60.3	58.8	59.2
70-79	46.4	47.8	47.9	48.3	49.2	50.1	50.4	50.9	51.5	49.7	50.7
80+	33.2	37.5	36.8	36.3	36.8	37.6	38.6	38.8	38.6	37.4	37.3
Male	60.0	60.8	61.0	60.7	61.4	62.9	63.2	64.0	64.1	63.5	63.6
Female	61.9	62.0	62.0	61.2	62.3	62.4	63.3	63.5	64.0	62.9	62.7
White	55.9	56.5	56.5	55.8	56.8	57.2	58.1	58.8	58.9	57.7	58.2
Black	69.6	69.3	69.8	68.9	70.0	70.7	71.0	71.0	71.4	71.6	70.6
Other race	67.2	71.6	71.6	74.9	73.1	75.1	73.2	71.7	71.9	73.1	72.2
†Hispanic									70.5	70.4	70.7
†Non-Hispanic									63.2	62.3	62.2
Diabetes	55.1	56.8	56.4	57.3	58.2	60.5	60.1	60.8	61.4	60.5	60.4
Hypertension	59.3	60.1	60.1	59.3	60.5	61.0	61.6	63.3	63.3	61.9	61.8
Glomerulonephritis	73.6	72.2	73.5	71.7	74.4	75.9	74.7	76.3	76.9	76.7	78.0
Other cause	63.7	64.4	65.4	64.2	64.3	62.5	66.0	64.1	64.3	64.9	64.8
All	60.9	61.4	61.5	60.9	61.9	62.7	63.3	63.8	64.0	63.2	63.2

Table I.25

Two-year Survival Probabilities: Incident Dialysis Patients, Adjusted

censored at transplant, from day 91 to two years + 90 days, adjusted for age, gender, race, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-19	88.6	91.0	89.9	89.7	90.0	90.7	91.3	92.7	91.7	92.0	91.5
20-44	78.4	78.7	79.6	78.5	79.8	80.4	80.8	80.9	81.9	82.7	82.7
45-64	64.8	66.1	66.7	67.3	68.1	69.2	70.4	70.9	71.7	72.4	72.2
65-74	52.9	54.1	55.0	54.6	56.5	57.0	57.5	57.7	58.3	57.3	57.8
75+	38.9	42.1	41.8	42.7	43.1	44.2	44.7	44.2	45.1	44.1	43.4
Male	57.8	59.9	60.3	60.7	61.6	63.0	63.6	64.0	64.8	64.7	65.0
Female	61.1	61.9	62.6	62.3	63.6	64.0	64.9	65.0	65.6	65.6	65.2
White	56.0	57.6	57.9	58.0	59.2	60.2	61.1	61.5	62.4	62.0	62.6
Black	65.0	65.6	66.7	66.7	67.7	68.4	68.9	69.0	69.5	69.9	68.9
Other race	65.1	68.8	69.3	69.6	70.2	71.3	71.5	70.6	71.5	72.5	71.3
Diabetes	52.5	54.3	54.8	55.5	56.8	58.7	59.4	59.7	60.7	60.8	61.3
Hypertension	62.3	63.7	64.2	63.6	64.7	65.4	65.9	67.0	67.7	67.2	67.1
Glomerulonephritis	69.3	69.3	70.2	70.0	71.8	72.8	73.0	73.7	74.2	74.2	75.1
Other cause	64.7	66.1	66.5	66.5	66.8	66.0	67.4	66.2	66.6	66.7	65.3
All	59.4	60.9	61.4	61.5	62.6	63.5	64.2	64.5	65.2	65.1	65.1

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Unknown age, gender; other & unknown, & primary diagnosis are excluded. †CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank. Includes U.S. & territories; no unknown or foreign states.

Table I.26

Five-year Survival Probabilities: Incident Dialysis Patients, Unadjusted*censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-4	65.0	86.3	80.3	67.9	75.5	69.5	70.4	70.4	73.0	74.4	82.0
5-9	68.5	74.2	81.6	92.9	90.2	79.8	95.7	71.5	75.2	87.5	85.5
10-14	96.2	79.2	85.1	80.2	86.0	81.8	82.9	78.1	81.3	82.5	87.1
15-19	70.7	75.9	83.2	77.6	79.4	85.8	81.4	85.9	80.0	82.4	86.4
20-29	59.5	65.7	62.1	67.6	64.1	66.9	67.4	69.5	70.9	73.7	74.4
30-39	51.0	51.5	49.2	55.4	55.7	55.2	54.5	55.9	59.0	58.8	60.7
40-49	47.1	47.3	47.2	49.0	46.3	48.1	47.3	48.6	49.9	51.2	54.0
50-59	34.3	35.2	36.3	35.7	35.8	35.4	37.5	36.9	39.4	40.7	42.1
60-64	26.2	27.4	26.2	27.9	27.9	28.3	28.7	29.0	30.2	32.0	31.7
65-69	22.3	22.2	22.7	22.6	22.5	22.6	21.8	23.7	24.0	25.1	24.9
70-79	15.5	15.0	15.5	15.6	16.2	15.7	16.1	16.2	16.8	17.1	17.7
80+	8.6	7.7	8.1	6.8	9.1	8.9	7.8	7.8	8.3	8.6	9.7
Male	27.5	28.2	28.1	28.9	29.2	28.8	28.9	28.9	30.4	31.4	33.6
Female	31.3	30.6	29.9	30.7	29.5	29.6	28.9	29.7	29.9	31.4	32.2
White	25.0	24.3	23.9	23.7	23.5	23.0	22.8	23.1	23.7	24.7	25.8
Black	37.4	38.1	37.5	39.9	38.6	39.4	38.8	39.1	39.7	41.1	43.1
Other race	31.3	35.9	36.6	38.1	41.6	40.2	40.7	40.4	42.1	43.6	42.2
†Hispanic											
†Non-Hispanic											
Diabetes	18.0	20.1	19.9	21.4	21.4	21.4	22.3	22.9	24.6	25.3	26.3
Hypertension	30.8	29.2	28.0	29.3	29.5	29.5	28.3	29.1	29.5	30.2	33.3
Glomerulonephritis	40.3	40.6	41.4	43.6	42.4	43.0	43.0	44.1	46.7	46.3	49.5
Other cause	34.4	34.7	35.5	34.7	35.6	35.3	35.3	34.8	33.3	38.4	38.4
All	29.4	29.3	29.0	29.8	29.4	29.2	28.9	29.3	30.1	31.4	32.9

Table I.27

Five-year Survival Probabilities: Incident Dialysis Patients, Adjusted*censored at transplant, from day 91 to five years + 90 days, adjusted for age, gender, race, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-19	68.5	73.7	79.1	73.3	78.1	75.2	75.1	75.3	76.8	78.5	82.0
20-44	50.0	52.1	50.8	53.9	53.7	54.7	53.2	54.7	55.8	56.7	57.6
45-64	30.8	32.2	32.3	33.6	34.4	34.7	36.0	36.1	37.5	39.6	41.0
65-74	18.9	19.3	19.9	20.5	20.9	21.2	21.3	22.3	22.7	23.4	24.3
75+	10.3	10.4	10.2	9.9	11.3	10.8	11.6	11.3	11.9	12.4	12.5
Male	26.1	27.5	27.5	28.2	29.5	29.6	30.3	30.6	32.1	33.1	34.2
Female	29.6	30.2	30.3	31.7	31.7	32.0	32.1	32.9	33.2	34.6	35.4
White	24.7	25.3	25.4	25.9	26.6	26.5	26.9	27.5	28.4	29.8	31.0
Black	32.6	33.7	33.9	35.7	35.6	36.5	36.9	37.4	38.2	39.3	40.2
Other race	30.7	34.8	33.9	35.8	39.7	39.9	40.7	40.7	42.2	42.9	42.3
Diabetes	19.5	20.8	21.1	22.6	23.5	23.7	24.6	25.2	27.1	28.2	29.2
Hypertension	31.9	32.3	31.5	32.6	33.4	33.6	33.2	33.9	34.6	35.6	37.8
Glomerulonephritis	39.0	39.4	39.8	41.4	40.4	41.3	41.4	43.1	44.6	45.2	46.9
Other cause	33.7	35.3	35.4	35.4	36.3	36.4	36.7	36.5	35.4	37.6	36.7
All	27.7	28.8	28.8	29.9	30.5	30.8	31.2	31.7	32.6	33.8	34.8

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender, other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.28

Ten-year Survival Probabilities: Incident Dialysis Patients, Unadjusted

censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-4	77.6	73.7	65.1	66.9	59.7	32.5	86.3	80.3	50.9	75.5	50.7
5-9	88.7	67.4	52.6	78.9	84.4	58.7	74.2	81.6	92.9	82.0	63.8
10-14	60.1	57.9	63.1	80.2	64.1	87.5	72.0	80.1	63.0	63.4	66.4
15-19	78.5	62.1	66.7	72.2	60.5	55.3	56.4	62.3	64.2	65.8	65.4
20-29	53.7	47.1	47.9	43.8	43.6	42.4	42.9	41.6	45.8	41.9	45.4
30-39	39.2	35.0	31.3	32.8	31.8	29.9	29.3	28.1	29.6	31.3	31.9
40-49	24.7	23.9	22.8	22.0	23.8	21.6	21.2	21.4	22.9	19.3	20.4
50-59	13.0	14.1	14.0	11.8	11.2	12.3	10.6	11.3	10.7	10.7	10.5
60-64	7.9	7.8	6.1	7.5	6.9	7.4	7.0	6.2	6.8	6.1	6.0
65-69	4.6	4.9	3.9	4.9	5.1	5.8	4.8	4.2	4.4	4.1	4.6
70-79	2.6	2.2	2.9	2.4	2.9	2.8	2.4	2.7	2.4	2.1	2.0
80+	1.2	1.2	1.6	0.4	1.5	1.2	0.7	1.1	0.5	0.8	0.6
Male	13.6	12.5	11.5	10.3	10.4	9.9	9.7	9.4	9.3	8.8	9.2
Female	15.6	15.5	13.0	11.7	11.3	11.1	9.6	9.2	9.8	8.9	8.6
White	13.1	11.4	10.4	9.0	8.8	8.1	7.2	7.1	6.5	5.9	6.0
Black	16.8	17.8	15.6	14.3	14.3	14.7	13.5	13.0	14.5	13.6	13.6
Other race	12.9	15.1	14.8	15.4	14.1	12.3	14.8	13.0	14.1	13.8	13.9
Diabetes	6.3	5.2	4.7	4.6	4.4	4.4	4.2	4.4	4.6	4.1	4.2
Hypertension	13.8	12.4	10.9	11.1	10.6	10.3	9.4	8.2	8.9	9.0	8.5
Glomerulonephritis	27.4	22.8	20.1	18.6	19.3	17.8	17.5	17.3	17.9	16.4	17.9
Other cause	14.5	16.1	15.7	12.6	13.3	13.9	12.9	13.4	13.4	13.2	13.9
All	14.5	13.9	12.2	11.0	10.8	10.5	9.6	9.3	9.6	8.9	8.9

Table I.29

Ten-year Survival Probabilities: Incident Dialysis Patients, Adjusted

censored at transplant, from day 91 to ten years + 90 days, adjusted for age, gender, race, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-17	69.7	53.0	54.6	60.2	50.1	47.9	53.3	61.5	51.7	58.2	53.8
18-29	32.2	28.8	27.1	28.8	27.7	26.3	26.5	25.1	27.4	26.2	27.4
30-44	11.4	10.6	10.7	10.5	10.3	10.7	10.3	10.3	10.6	10.4	10.7
45-54	3.5	3.3	3.7	3.2	4.1	4.4	3.9	4.1	4.0	3.8	4.0
55+	1.1	1.0	1.0	0.7	1.2	1.5	1.2	1.2	1.0	1.1	1.1
Male	11.0	10.1	10.0	10.0	10.1	10.0	10.0	9.9	10.1	10.2	10.5
Female	13.2	12.2	12.0	12.1	12.1	12.1	11.6	11.5	12.1	11.4	11.9
White	11.2	9.5	9.2	9.4	9.0	8.9	8.5	8.4	8.4	8.2	8.3
Black	13.2	13.2	13.0	12.6	13.6	13.7	13.4	13.4	14.2	13.4	14.2
Other race	12.0	11.2	13.0	13.6	12.8	12.4	14.1	13.5	14.3	16.2	16.5
Diabetes	6.4	5.1	5.0	5.9	5.6	5.8	5.9	6.1	6.6	6.5	6.8
Hypertension	15.5	13.5	12.9	13.5	12.5	12.9	12.2	11.6	12.1	11.9	12.3
Glomerulonephritis	21.8	19.4	18.4	18.2	19.1	18.0	17.2	17.4	18.2	16.7	17.6
Other cause	13.5	14.2	15.2	13.3	14.5	14.1	14.2	14.2	13.9	13.8	14.0
All	12.0	11.0	10.9	10.9	11.0	10.9	10.7	10.6	11.0	10.7	11.1

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Unknown age, gender; other & unknown, & primary diagnosis are excluded. †CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank. Includes U.S. & territories; no unknown or foreign states.

Table I.30

One-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Unadjusted*from day of transplant to one year, by age, gender, race, & ethnicity, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-17	96.1	95.6	97.1	99.0	97.1	97.8	97.6	98.8	98.8	98.6	98.2
18-29	96.1	96.7	97.4	97.0	96.9	97.2	97.3	98.3	98.4	98.2	97.8
30-44	94.2	94.5	95.8	95.4	96.2	95.8	96.3	96.2	96.4	97.0	97.0
45-54	92.0	92.2	94.6	93.5	92.9	93.8	94.1	94.4	93.8	94.8	94.7
55+	87.9	88.4	89.9	89.5	89.7	89.8	89.8	91.1	90.1	91.0	90.3
Male	92.2	92.8	94.3	93.7	93.9	93.8	94.2	94.6	94.3	94.7	94.5
Female	93.9	93.6	95.0	94.3	94.1	94.6	94.6	94.8	94.1	95.0	94.4
White	92.7	92.7	94.4	93.5	93.8	93.6	93.7	94.5	94.1	94.6	94.4
Black	93.5	94.3	94.9	94.4	94.2	94.7	95.6	95.0	93.8	94.8	94.4
Other race	92.8	93.6	95.4	96.8	95.4	96.4	94.9	94.7	96.5	96.4	94.7
†Hispanic								96.9	97.1	96.7	95.0
†Non-Hispanic								94.5	93.9	94.6	94.4
Diabetes	91.4	90.9	91.4	91.7	91.6	92.0	92.4	92.6	92.8	93.2	92.8
Hypertension	92.4	92.3	95.3	92.9	93.5	93.9	94.1	95.0	92.9	94.7	93.0
Glomerulonephritis	94.3	94.9	95.7	96.0	96.5	96.4	95.8	95.5	95.7	96.1	96.4
Other cause	93.2	93.6	95.6	94.7	94.5	94.4	95.0	95.7	95.2	95.6	95.5
All	92.9	93.1	94.6	94.0	94.0	94.1	94.3	94.7	94.2	94.8	94.4

Table I.31

One-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Adjusted*from day of transplant to one year, adjusted for age, gender, race, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-17	97.4	97.3	98.1	98.5	97.7	98.2	98.2	97.7	98.4	99.0	98.5
18-29	96.2	96.6	97.6	97.1	97.1	97.6	97.2	97.6	97.5	98.4	97.5
30-44	94.4	94.8	95.9	95.7	96.1	95.9	96.3	96.7	96.5	97.2	96.8
45-54	91.1	91.3	93.6	93.1	93.4	93.8	94.1	94.3	94.2	94.8	95.1
55+	86.4	87.2	89.8	88.6	89.0	89.5	90.0	91.3	90.4	91.2	90.7
Male	91.5	92.1	93.7	93.4	93.7	93.8	94.3	94.9	94.7	95.2	94.9
Female	92.5	92.6	94.6	93.7	94.0	94.4	94.3	94.8	94.4	95.4	95.1
White	92.2	92.3	94.2	93.7	93.9	94.0	94.3	95.0	94.6	95.4	95.1
Black	90.8	91.7	93.4	92.8	93.2	93.6	94.2	94.5	94.2	94.8	94.6
Other race	93.2	94.2	94.8	95.3	96.1	95.8	95.8	95.8	95.7	96.6	95.2
Diabetes	88.0	88.4	91.1	89.9	90.7	91.3	92.4	92.6	92.4	93.5	93.4
Hypertension	92.1	92.7	94.5	93.7	94.1	94.3	94.0	94.9	94.9	95.7	94.6
Glomerulonephritis	94.1	94.5	95.5	95.3	95.5	95.6	95.4	96.1	95.5	96.2	96.2
Other cause	93.5	93.8	95.3	95.3	95.2	95.1	95.4	95.9	95.6	95.9	95.8
All	91.9	92.3	94.0	93.5	93.8	94.0	94.3	94.9	94.6	95.3	95.0

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.32

Two-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Unadjusted

from day of transplant to two years, by age, gender, race, ethnicity, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-17	94.6	95.6	94.4	96.7	97.6	95.9	96.0	96.8	96.9	98.0	98.2
18-29	94.2	94.3	94.5	95.4	95.2	95.2	96.5	96.1	97.0	96.4	97.4
30-44	90.5	91.3	91.9	93.6	92.5	94.0	93.3	94.5	94.3	94.6	95.2
45-54	86.2	87.7	88.5	91.2	90.3	88.8	89.9	91.1	90.8	90.8	91.9
55+	81.8	81.7	84.5	85.5	84.1	84.9	84.7	85.3	86.4	86.1	86.4
Male	87.7	88.6	89.8	91.3	90.5	90.7	90.3	91.3	91.7	91.3	91.6
Female	90.0	90.6	90.6	92.3	90.9	91.1	91.8	92.3	91.5	91.7	92.6
White	88.5	89.4	89.8	91.5	90.3	90.6	90.3	91.2	91.3	91.2	92.1
Black	88.7	89.1	90.7	91.9	90.9	90.8	91.3	92.5	91.9	91.5	91.0
Other race	89.2	90.2	91.7	93.1	93.7	94.0	93.8	93.1	93.0	93.5	94.4
†Hispanic									93.7	94.9	95.8
†Non-Hispanic									91.5	91.1	91.6
Diabetes	83.2	86.3	86.0	86.9	86.4	87.3	87.6	88.7	88.6	88.4	89.4
Hypertension	89.6	88.0	88.9	92.2	88.8	90.0	91.1	90.9	91.2	90.4	91.7
Glomerulonephritis	90.7	91.7	93.2	94.0	94.3	94.4	94.1	94.1	93.3	93.8	94.5
Other cause	89.6	90.4	91.2	93.1	92.1	91.8	91.1	92.9	93.3	93.2	93.1
All	88.6	89.4	90.1	91.7	90.6	90.8	90.9	91.7	91.6	91.4	92.0

Table I.33

Two-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Adjusted

from day of transplant to two years, adjusted for age, gender, race, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-17	95.3	96.1	96.1	97.0	97.7	96.5	97.2	97.3	96.4	97.6	98.4
18-29	94.4	94.2	95.0	96.2	95.4	95.5	96.2	95.9	96.2	96.3	97.5
30-44	90.6	91.6	92.5	93.6	93.3	93.9	93.5	94.5	94.7	94.8	95.6
45-54	85.3	86.7	87.7	90.3	89.3	90.0	90.4	91.3	91.0	91.4	92.0
55+	78.9	80.0	81.9	84.5	82.6	83.4	83.9	85.5	86.4	85.9	86.5
Male	86.4	87.4	88.7	90.4	89.8	90.3	90.4	91.7	92.0	92.1	92.6
Female	87.8	88.8	89.5	91.8	90.3	90.9	91.3	91.7	91.8	91.7	93.0
White	87.3	88.3	89.1	91.2	90.2	90.6	90.8	91.6	92.1	92.1	92.9
Black	85.4	86.4	88.2	90.0	88.9	89.6	90.2	91.5	91.3	91.4	92.0
Other race	89.3	89.9	91.7	92.1	92.8	94.0	93.5	93.7	93.3	93.6	94.7
Diabetes	80.4	82.3	83.6	86.5	84.6	85.9	86.7	88.9	88.5	88.8	90.1
Hypertension	88.0	88.2	89.6	91.6	90.2	91.0	91.1	91.1	92.0	92.5	93.3
Glomerulonephritis	90.2	91.1	92.1	93.1	92.7	93.0	93.1	93.3	93.8	93.3	94.1
Other cause	89.6	90.3	91.1	92.8	92.7	92.6	92.4	93.2	93.5	93.5	93.7
All	86.9	87.9	89.0	90.9	90.0	90.5	90.7	91.7	91.9	92.0	92.7

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.34

Five-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Unadjusted*from day of transplant to five years, by age, race, gender, ethnicity, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-17	88.3	88.7	92.9	89.1	91.7	92.8	91.0	94.7	93.4	94.1	94.0
18-29	85.8	83.7	87.9	88.3	87.1	89.1	90.2	89.7	89.8	91.4	90.7
30-44	76.4	75.6	76.2	79.5	82.6	83.8	84.9	84.0	85.8	84.9	86.7
45-54	65.2	64.0	67.6	72.6	75.3	75.0	78.3	76.0	76.9	79.9	79.4
55+	56.4	58.4	58.3	64.0	65.3	68.1	66.2	66.4	66.4	66.4	67.7
Male	73.2	70.9	72.3	75.1	77.5	78.7	78.7	78.8	79.1	79.4	80.2
Female	77.0	77.0	78.2	79.1	81.0	81.3	83.1	80.0	81.0	81.8	81.9
White	75.6	73.4	74.7	76.9	78.9	79.1	80.6	79.1	79.8	80.3	80.2
Black	70.4	70.7	72.0	75.3	78.0	80.6	79.4	78.2	78.4	79.4	81.0
Other race	82.1	80.8	83.0	79.5	82.1	83.6	82.1	85.6	87.0	84.0	87.3
†Hispanic											
†Non-Hispanic											
Diabetes	62.7	61.3	62.8	65.8	71.0	70.4	72.7	69.4	71.6	72.8	74.8
Hypertension	71.1	72.8	69.6	75.7	75.7	78.2	79.7	76.4	77.6	79.1	77.5
Glomerulonephritis	83.4	79.9	81.1	81.7	84.8	85.3	84.3	86.3	86.2	85.7	85.1
Other cause	75.9	75.2	78.6	79.7	81.2	82.5	83.3	83.1	83.4	83.5	84.8
All	74.6	73.1	74.6	76.7	78.9	79.8	80.4	79.3	79.9	80.3	80.9

Table I.35

Five-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Adjusted*from day of transplant to five years, adjusted for age, gender, race, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-17	88.3	88.5	91.1	89.8	91.8	91.6	92.4	94.5	91.7	93.6	93.5
18-29	86.0	83.8	86.6	88.0	88.0	89.3	90.6	89.2	89.7	91.3	90.1
30-44	76.6	75.7	76.7	80.4	82.8	84.2	84.6	84.7	86.1	85.6	86.9
45-54	62.7	63.7	67.3	70.4	73.8	74.9	77.1	76.3	77.8	79.2	79.8
55+	50.0	51.0	54.0	59.5	62.2	64.6	65.4	63.5	65.1	66.7	67.8
Male	67.0	66.8	69.1	72.9	75.3	77.2	77.8	77.8	78.9	79.5	80.9
Female	69.4	69.6	72.0	75.3	77.8	78.7	80.6	78.6	80.1	81.2	80.9
White	69.3	69.2	70.8	74.5	77.0	77.9	79.3	78.5	79.5	80.2	80.7
Black	63.1	63.0	67.7	71.1	73.6	76.3	76.9	76.0	77.5	79.0	80.5
Other race	74.2	74.6	74.7	78.1	79.9	82.9	81.3	83.7	86.4	85.6	85.4
Diabetes	54.6	54.7	58.7	62.3	66.4	67.9	69.6	67.5	70.2	72.2	75.2
Hypertension	70.8	70.4	70.8	75.5	76.7	78.7	80.1	78.3	80.0	80.8	79.7
Glomerulonephritis	76.4	75.8	76.5	79.7	82.0	83.6	83.3	83.4	84.3	84.9	84.2
Other cause	71.7	72.0	75.4	78.5	80.5	81.6	82.8	83.4	83.3	83.4	84.2
All	67.9	67.8	70.2	73.8	76.2	77.7	78.8	78.1	79.3	80.1	80.9

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.36

Ten-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Unadjusted

from day of transplant to ten years, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-17	81.1	77.7	79.0	83.3	81.5	80.2	82.0	85.4	82.2	86.0	86.0
18-29	67.4	70.9	70.6	72.7	72.6	73.9	71.2	77.5	77.0	75.8	77.2
30-44	49.2	50.5	55.3	55.3	54.9	58.0	57.0	57.4	62.2	64.0	65.9
45-54	36.4	38.7	37.4	37.4	41.6	39.6	41.1	45.6	47.5	51.2	50.8
55+	21.6	20.7	26.5	26.6	26.0	25.8	27.2	31.3	34.3	36.0	37.2
Male	50.5	52.1	52.6	53.7	52.2	54.0	51.4	53.4	54.5	56.8	57.7
Female	54.8	56.4	59.4	57.7	59.0	57.7	58.0	59.9	59.6	61.9	61.3
White	53.1	55.7	55.9	57.1	55.5	57.2	54.3	56.6	57.2	59.7	58.8
Black	46.8	45.0	50.5	46.3	50.7	48.8	48.9	51.4	52.8	54.9	57.5
Other race	59.9	58.9	68.0	71.0	63.3	62.7	69.2	65.6	63.2	63.7	68.5
Diabetes	28.9	37.4	37.0	33.4	34.9	37.2	35.7	38.9	39.5	44.0	43.9
Hypertension	52.6	49.7	52.5	51.3	49.2	48.5	47.6	48.3	50.5	52.8	54.4
Glomerulonephritis	66.6	65.0	65.0	66.2	64.0	68.3	66.6	65.2	65.8	68.5	69.2
Other cause	49.3	52.5	55.7	57.0	58.6	58.2	57.5	62.1	62.3	64.0	64.0
All	52.1	53.6	55.1	55.1	54.7	55.4	53.8	55.9	56.5	58.8	59.1

Table I.37

Ten-year Survival Probabilities: First Transplant Patients (Cadaveric Donor), Adjusted

from day of transplant to ten years, adjusted for age, gender, race, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-17	77.1	74.2	77.5	79.6	79.0	76.7	77.6	82.3	78.6	81.8	80.7
18-29	63.7	65.3	67.3	68.9	68.7	72.6	69.3	74.2	75.1	74.2	76.0
30-44	45.9	49.0	54.2	53.4	54.4	57.0	56.3	57.9	61.5	64.5	65.9
45-54	32.2	34.9	34.2	35.1	38.1	37.8	39.9	44.4	46.1	49.7	50.0
55+	22.5	20.3	22.7	24.9	23.2	24.1	25.8	28.7	32.2	33.9	35.5
Male	39.2	40.4	42.0	43.7	43.2	45.1	45.3	48.3	51.0	53.3	55.0
Female	40.3	42.0	45.8	45.1	47.7	48.2	48.9	52.3	54.5	57.1	57.3
White	40.6	43.9	44.3	45.7	46.4	48.0	48.4	50.6	53.3	55.9	56.1
Black	34.8	32.6	38.6	38.1	39.4	40.4	40.7	46.6	48.5	50.7	53.6
Other race	51.6	48.0	56.8	57.3	54.5	54.7	55.8	56.0	58.7	60.4	64.4
Diabetes	24.0	27.9	27.8	28.5	28.1	30.4	30.8	35.1	36.6	40.3	40.9
Hypertension	44.3	44.6	48.9	48.6	47.5	49.4	49.3	50.0	54.2	54.9	56.8
Glomerulonephritis	51.6	49.9	53.0	55.7	55.1	57.3	57.0	58.2	60.8	63.5	65.2
Other cause	42.1	43.9	47.2	47.4	50.8	50.6	51.6	56.5	58.9	61.0	61.7
All	39.6	41.0	43.5	44.2	44.9	46.3	46.7	49.8	52.3	54.7	55.9

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Unknown age, gender, other & unknown, & primary diagnosis are excluded. †CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank. Includes U.S. & territories; no unknown or foreign states.

Table I.38

One-year Survival Probabilities: First Transplant Patients (Living Donor), Unadjusted*from day of transplant to one year, by age, gender, race, ethnicity, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-17	97.7	97.2	99.1	96.8	98.0	98.5	97.4	99.1	99.4	99.1	99.7
18-29	98.0	99.3	98.8	98.2	98.7	99.7	99.1	99.5	99.1	99.7	99.3
30-44	98.3	98.2	98.2	98.3	98.0	98.2	98.4	98.9	98.6	98.6	98.6
45-54	98.3	96.1	97.5	96.9	96.5	97.2	97.2	97.2	95.8	97.4	98.0
55+	91.4	91.7	93.0	92.4	94.0	95.4	93.4	94.4	95.7	95.0	96.0
Male	97.3	97.7	97.9	97.4	97.4	97.3	97.2	98.1	98.1	97.8	97.7
Female	98.1	97.5	98.0	97.0	97.5	99.0	97.9	97.8	96.9	97.9	98.6
White	97.6	97.4	98.0	97.3	97.6	98.2	97.5	97.9	97.5	98.0	98.1
Black	96.8	98.2	97.0	95.8	96.5	97.5	97.2	97.9	97.2	96.8	97.7
Other race	100.0	100.0	100.0	98.5	98.0	97.5	98.9	99.1	99.6	98.4	98.5
†Hispanic								97.8	99.0	98.7	98.8
†Non-Hispanic								98.0	97.4	97.7	98.0
Diabetes	98.2	96.2	95.8	95.6	95.1	96.8	96.0	96.8	95.0	95.5	97.0
Hypertension	96.9	94.4	97.4	96.9	97.0	97.2	96.8	97.4	97.0	97.9	97.2
Glomerulonephritis	96.7	98.4	98.6	98.0	98.7	98.8	98.5	99.0	98.9	99.2	98.3
Other cause	98.1	98.3	98.7	97.4	97.9	98.4	97.7	98.0	98.2	98.2	98.8
All	97.6	97.6	97.9	97.2	97.5	98.0	97.5	98.0	97.6	97.9	98.1

Table I.39

One-year Survival Probabilities: First Transplant Patients (Living Donor), Adjusted*from day of transplant to one year, adjusted for age, gender, race, & primary diagnosis*

	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-17	99.1	98.8	99.1	98.1	98.5	99.1	98.9	98.8	98.5	99.3	99.1
18-29	98.6	98.9	99.0	98.2	98.8	99.3	98.2	98.9	98.7	99.2	99.1
30-44	97.8	97.9	98.0	97.8	98.0	98.5	98.2	98.4	98.4	98.5	98.6
45-54	95.8	95.1	96.8	96.3	96.5	97.3	97.3	97.5	97.0	97.4	98.2
55+	92.3	92.4	95.5	93.6	93.9	95.2	94.6	96.5	95.9	96.3	96.2
Male	96.7	96.7	97.6	97.0	97.2	97.8	97.4	98.1	97.8	98.0	98.1
Female	96.9	96.6	97.5	96.7	97.2	98.0	97.6	97.9	97.8	98.2	98.6
White	97.0	97.0	97.7	97.0	97.3	98.1	97.4	98.0	97.7	98.2	98.4
Black	95.6	95.5	96.8	96.5	96.8	97.2	97.7	98.1	97.7	97.7	97.9
Other race	98.1	97.3	98.4	97.6	98.3	97.7	97.7	98.6	98.3	98.4	98.9
Diabetes	94.6	94.3	95.3	94.2	94.9	96.6	95.6	97.0	96.3	96.6	97.9
Hypertension	96.7	96.7	97.7	96.9	97.5	98.0	97.1	97.6	97.4	98.5	98.4
Glomerulonephritis	97.8	97.4	98.3	97.6	98.2	98.4	98.5	98.5	98.8	99.0	98.2
Other cause	97.5	97.7	98.5	97.9	97.8	98.3	98.0	98.5	98.0	98.3	98.6
All	96.8	96.7	97.6	96.9	97.2	97.9	97.5	98.0	97.8	98.1	98.3

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.40

Two-year Survival Probabilities: First Transplant Patients (Living Donor), Unadjusted

from day of transplant to two years, by age, gender, race, ethnicity, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-17	94.3	97.7	96.9	99.1	96.8	97.2	98.5	96.6	98.0	97.8	98.5
18-29	97.6	96.3	99.1	98.1	97.1	98.3	99.2	98.2	98.9	98.7	98.9
30-44	95.8	96.4	96.8	95.8	97.1	97.1	97.0	97.1	97.3	97.9	97.6
45-54	93.6	95.7	92.6	95.3	95.6	94.6	94.0	95.8	94.9	94.6	95.0
55+	84.3	89.1	88.2	90.3	90.6	91.7	90.8	88.9	92.0	93.8	93.5
Male	95.2	95.4	96.5	96.2	96.2	96.5	96.0	95.6	96.5	97.0	96.5
Female	95.3	96.7	95.9	96.4	95.8	96.0	96.9	96.1	96.0	95.9	96.6
White	95.2	96.1	96.1	96.2	96.3	96.6	96.8	95.8	96.3	96.5	96.7
Black	95.9	94.1	96.4	95.7	93.7	94.3	94.9	95.7	95.6	95.7	95.2
Other race	95.1	98.7	98.9	100.0	97.7	98.0	95.5	96.1	98.1	98.8	96.9
†Hispanic									97.1	98.3	97.9
†Non-Hispanic									96.2	96.3	96.3
Diabetes	92.1	94.9	94.3	92.2	92.7	93.1	94.5	92.2	93.9	93.0	92.7
Hypertension	94.6	96.3	92.5	96.5	95.5	94.9	95.6	95.2	94.7	96.1	97.0
Glomerulonephritis	97.2	95.6	97.3	97.8	97.4	98.1	97.6	97.0	98.0	98.7	98.5
Other cause	95.5	96.6	97.1	97.3	96.8	97.0	96.7	96.8	96.8	96.9	97.1
All	95.3	95.9	96.2	96.3	96.0	96.3	96.3	95.8	96.3	96.5	96.5

Table I.41

Two-year Survival Probabilities: First Transplant Patients (Living Donor), Adjusted

from day of transplant to two years, adjusted for age, gender, race, & primary diagnosis

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
0-17	97.1	98.5	98.1	98.4	97.3	97.9	98.2	98.1	97.8	97.8	98.8
18-29	97.6	97.7	98.3	98.2	97.5	98.2	98.6	97.0	97.9	98.2	98.6
30-44	94.7	96.4	96.7	96.4	96.9	97.2	97.3	97.0	97.1	97.7	97.6
45-54	92.6	92.9	92.4	94.3	94.8	95.0	95.0	95.4	95.5	95.6	95.8
55+	86.5	87.3	88.3	92.1	91.1	91.2	91.2	91.0	93.7	94.1	93.9
Male	93.7	94.5	94.9	95.8	95.9	96.0	96.0	95.7	96.6	96.8	96.8
Female	93.7	94.9	94.8	95.6	95.4	96.0	96.3	95.9	96.2	96.8	97.1
White	94.1	94.9	95.3	95.9	95.7	96.0	96.5	95.7	96.3	96.7	97.0
Black	91.6	92.8	93.0	94.4	95.1	95.4	94.8	96.1	96.5	96.7	96.3
Other race	94.3	96.8	95.8	97.1	96.6	97.5	95.8	96.1	97.4	97.5	97.4
Diabetes	89.1	91.1	91.2	91.7	91.9	92.7	93.8	92.6	94.5	94.7	94.5
Hypertension	94.0	94.5	94.8	95.9	95.7	96.3	96.2	95.1	95.6	96.3	97.6
Glomerulonephritis	96.0	96.3	95.9	96.9	96.7	97.3	97.1	97.5	97.2	98.2	98.3
Other cause	94.7	95.8	96.5	97.3	97.1	96.8	96.9	96.6	97.3	97.1	97.1
All	93.7	94.6	94.9	95.7	95.7	96.0	96.2	95.8	96.4	96.8	96.9

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Unknown age, gender, other & unknown, & primary diagnosis are excluded. †CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank. Includes U.S. & territories; no unknown or foreign states.

Table I.42

Five-year Survival Probabilities: First Transplant Patients (Living Donor), Unadjusted*from day of transplant to five years, by age, gender, race, ethnicity, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-17	97.2	93.7	94.1	91.9	96.2	94.5	97.8	93.6	94.6	97.3	95.4
18-29	91.7	90.8	92.3	94.1	94.1	96.7	95.6	94.2	95.1	95.9	93.4
30-44	87.6	89.7	89.1	87.6	90.4	91.3	90.3	91.9	91.5	91.4	92.7
45-54	82.3	88.3	88.2	85.7	85.7	83.6	84.1	86.7	85.0	86.6	89.2
55+	83.3	84.2	82.2	71.9	73.4	75.7	80.5	80.8	73.6	72.2	76.4
Male	87.7	88.7	88.9	89.5	90.6	91.6	91.0	91.1	89.6	89.2	90.1
Female	89.2	90.5	90.0	88.7	90.3	90.2	91.0	89.8	89.4	90.5	90.2
White	88.3	89.4	89.0	90.2	90.7	90.7	91.2	91.1	89.8	90.6	89.9
Black	87.2	89.8	90.2	83.4	86.8	91.9	87.8	86.5	87.4	87.5	90.4
Other race	90.6	89.4	91.0	87.7	97.3	94.6	96.2	93.1	91.8	86.0	91.6
†Hispanic											
†Non-Hispanic											
Diabetes	75.7	80.9	79.6	82.1	85.1	84.4	80.3	81.9	80.0	81.4	81.8
Hypertension	91.0	90.9	91.3	83.7	86.4	85.0	89.4	90.0	87.3	86.7	87.0
Glomerulonephritis	90.6	91.9	92.5	94.2	92.5	93.9	94.2	93.5	93.9	94.2	94.3
Other cause	92.0	91.6	91.3	90.0	92.3	93.2	94.4	92.5	91.7	92.0	92.1
All	88.3	89.4	89.3	89.2	90.5	91.0	91.0	90.5	89.6	89.8	90.1

Table I.43

Five-year Survival Probabilities: First Transplant Patients (Living Donor), Adjusted*from day of transplant to five years, adjusted for age, gender, race, & primary diagnosis*

	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995
0-17	95.9	94.5	94.3	93.2	96.4	95.3	95.9	93.4	93.7	94.9	95.5
18-29	93.2	94.0	93.5	94.4	94.4	95.8	95.3	93.9	94.6	95.9	92.8
30-44	88.9	90.4	90.5	87.7	91.3	92.1	91.2	92.5	91.7	92.1	92.7
45-54	82.4	85.9	85.9	83.2	83.6	82.2	86.2	87.7	85.8	85.9	89.2
55+	75.9	79.0	79.6	71.0	71.9	73.7	81.3	79.4	76.1	76.3	79.5
Male	86.6	88.2	88.3	85.9	87.3	88.2	89.9	90.1	88.7	88.9	89.9
Female	87.2	89.2	89.2	85.8	88.2	87.8	89.3	89.1	88.7	89.8	90.5
White	87.6	88.9	88.8	86.8	88.3	88.9	90.1	89.9	88.8	90.2	89.9
Black	83.4	86.8	87.5	81.6	83.7	84.1	86.6	88.4	87.1	85.8	90.8
Other race	88.0	91.4	91.0	87.0	92.4	90.1	93.0	91.8	92.9	88.3	90.9
Diabetes	75.7	79.1	80.6	76.4	80.1	80.1	80.5	81.2	80.2	83.2	83.0
Hypertension	89.5	89.0	89.2	86.3	87.3	87.8	90.0	89.6	89.5	89.4	88.6
Glomerulonephritis	90.5	92.0	91.6	90.7	91.3	90.2	92.2	91.9	92.3	91.7	94.1
Other cause	89.8	91.6	91.0	87.9	90.0	91.5	93.1	92.9	90.9	91.2	91.9
All	86.9	88.6	88.7	85.9	87.7	88.1	89.6	89.7	88.7	89.3	90.1

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.

Table I.44

Ten-year Survival Probabilities: First Transplant Patients (Living Donor), Unadjusted

from day of transplant to ten years, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-17	79.1	85.6	83.5	81.2	90.1	93.8	87.4	87.5	87.9	91.5	90.2
18-29	86.9	82.8	81.6	81.0	81.8	82.4	81.9	81.1	88.9	86.4	89.1
30-44	69.7	66.0	67.5	71.5	72.4	73.1	74.3	74.6	71.4	78.4	80.0
45-54	52.0	54.3	59.4	64.4	64.7	63.1	68.2	66.5	65.5	65.4	58.6
55+	40.0	48.6	41.4	61.3	60.0	51.6	56.1	57.2	48.3	45.3	42.4
Male	74.8	70.1	71.0	73.2	74.9	72.2	72.0	72.8	77.2	77.8	78.8
Female	75.1	74.6	72.9	75.9	76.1	76.3	77.3	75.3	77.3	79.4	77.5
White	75.5	72.5	71.4	75.0	76.2	74.7	73.7	73.7	78.1	78.3	78.9
Black	71.8	65.0	72.9	67.8	66.5	66.7	72.0	72.8	71.4	75.9	72.7
Other race	72.3	75.0	73.4	82.7	85.6	79.5	83.4	76.8	77.8	88.0	80.4
Diabetes	51.7	46.0	48.1	46.5	49.7	52.0	55.7	57.1	61.4	63.0	63.3
Hypertension	69.0	75.0	64.9	74.8	77.2	71.7	71.8	72.0	70.1	72.8	68.1
Glomerulonephritis	83.1	79.8	82.3	82.0	79.6	81.5	81.4	79.9	84.1	83.9	82.6
Other cause	75.6	72.6	74.3	78.9	82.4	79.6	78.8	78.2	81.3	82.9	83.8
All	74.9	71.9	71.7	74.3	75.4	73.8	74.1	73.8	77.2	78.4	78.2

Table I.45

Ten-year Survival Probabilities: First Transplant Patients (Living Donor), Adjusted

from day of transplant to ten years, adjusted for age, gender, race, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990
0-17	80.3	84.2	80.9	80.0	86.8	90.0	85.7	85.2	85.0	91.1	87.6
18-29	83.6	79.9	79.8	80.3	83.8	83.9	84.4	83.1	87.5	86.5	88.8
30-44	69.9	68.5	68.1	74.2	74.7	74.7	76.1	76.1	73.9	79.4	79.8
45-54	50.7	50.2	58.8	58.1	60.9	62.3	66.5	66.1	65.6	64.0	59.0
55+	34.2	34.3	40.4	52.9	47.2	51.3	53.4	54.1	46.2	44.6	44.5
Male	62.9	62.2	64.5	68.0	70.5	71.3	72.0	72.0	71.5	72.7	72.8
Female	66.0	65.3	66.6	71.1	70.6	72.3	74.1	73.8	71.5	74.3	72.1
White	64.0	64.5	65.9	70.5	71.9	73.0	73.4	73.0	73.0	74.4	74.0
Black	63.8	59.7	62.0	61.5	61.5	65.6	69.2	70.4	64.3	66.3	65.2
Other race	69.1	62.0	70.4	78.3	81.0	73.7	78.9	77.6	73.5	82.6	76.4
Diabetes	47.7	43.2	43.7	42.6	47.5	51.6	53.8	56.2	55.2	59.4	57.4
Hypertension	67.8	71.6	67.1	73.4	75.9	76.1	72.8	73.4	71.6	72.1	71.2
Glomerulonephritis	70.5	70.0	74.9	77.6	75.8	78.1	79.6	78.8	80.0	79.9	76.2
Other cause	67.5	66.8	69.7	75.8	77.3	76.7	78.7	77.4	74.5	77.3	78.9
All	64.3	63.5	65.4	69.3	70.5	71.7	72.9	72.8	71.5	73.4	72.5

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Unknown age, gender; other & unknown, & primary diagnosis are excluded.

†CMS has only started collecting Hispanic ethnicity data as of April, 1995, so Hispanic data in years prior to 1995 has been left blank.

Includes U.S. & territories; no unknown or foreign states.